A Systematic review and Network Meta-analysis of pharmaceutical interventions used to manage chronic pain

^{1,2}Ash Shetty^{*}, ³Gayathri Delanerolle^{*}, ⁷Heitor Cavalini^{**}, Chunli Deng^{**}, ^{9,10}Xiaojie Yang, ¹¹Amy Boyd, ²Tacson Fernandez, ^{6,7}Peter Phiri, Arun Bhaskar⁸, ^{4,5,7}Jian Qing Shi,

Affiliations

1

2

3

4

5 6 7

8

- 9 ¹University College London Hospitals NHS Foundation Trust
- 10 ²University College London, UK
- 11 ³Nuffield Department of Primary Care Health Sciences, University of Oxford, OX3 7JX, Oxford, UK
- 12 ⁴Southern University of Science and Technology, Shenzhen, 518055, China
- 13 ⁵Psychology Department, Faculty of Environmental and Life Sciences, University of Southampton,
- 14 SO17 1BJ, Southampton, UK
- 15 ⁶Southern Health NHS Foundation Trust, SO40 2RZ, UK
- ⁸Imperial College Healthcare NHS Trust, London, UK 16
- ⁹School of Statistics and Mathematics, Yunnan University of Finance and Economics, China 17
- ¹⁰National Centre for Applied Mathematics Shenzhen, China 18
- ¹¹University of Oxford, UK 19 20

21 Corresponding author: Professor Ashish Shetty

- Consultant Pain Medicine/Professor in Pain Medicine 22
- 23 University College London
- 24 235, Euston Road, London NW1 2BU
- 25 ashetty@nhs.net
- 26
- 27
- Shared first author 28 Shared second author
- 29 30

Declarations

31 32 Funding

- 33 Not applicable
- 34

35 **Conflicts of interest**

- 36 AS has received funding from Neurokor, Boston Scientific and Medtronic. PP has received research 37 grants from Novo Nordisk, Queen Mary University of London, John Wiley & Sons, Otsuka, outside the 38 submitted work. All other authors report no conflict of interest. The views expressed are those of the 39 authors and not necessarily those of the NHS, the National Institute for Health Research, the 40 Department of Health and Social Care or the Academic institutions.
- 41 Availability of data and material
- 42 The authors will consider sharing the dataset gathered upon receipt of reasonable requests.
- 43 Code availability
- 44 The authors will consider sharing the novel code created upon receipt of reasonable requests.

45 Author contributions

- AS and GD developed the study protocol and embedded this within the POP project. GD and JQS 46 47 designed and completed the study analysis. The data extraction was completed by HC and CD. All 48 authors critically appraised and commented on previous versions of the manuscript. All authors read 49 and approved the final manuscript.
- 50 Ethics approval: Not applicable
- 51 Consent to participate: Not applicable
- 52 Consent for publication: All authors consented to publish this manuscript.
- 53 54
- 55
- 56
- 57
- 58
- 59

60 Abstract

61

Background: It is estimated 1.5 billion of the global population suffer from chronic pain with prevalence increasing with demographics including age. It is suggested long-term exposure to chronic could cause further health challenges reducing people's quality of life. Therefore, it is imperative to use effective treatment options.

66

Purpose: We explored the current pharmaceutical treatments available for chronic painmanagement to better understand drug efficacy and pain reduction.

69

Methods: A systematic methodology was developed and published in PROSPERO (CRD42021235384). Keywords of opioids, *acute pain, pain management, chronic pain, opiods, NSAIDs, and analgesics* were used across PubMed, Science direct, ProQuest, Web of science, Ovid Psych INFO, PROSPERO, EBSCOhost, MEDLINE, ClinicalTrials.gov and EMBASE. All randomised controlled clinical trials (RCTs), epidemiology and mixed-methods studies published in English between the 1st of January 1990 and 30th of April 2022 were included.

77

78 Data synthesis: A total of 119 studies were included. The data was synthesised using a tri-79 partied statistical methodology of a meta-analysis (24), pairwise meta-analysis (24) and 80 network meta-analysis (34).

81

Limitations: Small sample sizes, lack of uniformity with pain assessments and sub-optimal clinical trial designs were observed within the pooled data.

84

85 Conclusion: Chronic pain is a public health problem that requires far more effective 86 pharmaceutical interventions with minimal better side-effect profiles which will aid to develop 87 better clinical guidelines. The importance of understanding ubiquity of pain by clinicians, 88 policy makers, researchers and academic scholars is vital to prevent social determinant 89 which aggrevates issues.

- 90
- 91
- 92
- 93 94
- 95
- 96
- 97
- 98
- 99 100
- 101
- 102
- 103
- 104 105
- 105
- 107
- 108 109
- 110
- 111
- 112
- 113 114

116 Introduction

117

115

118 Chronic non-cancer pain conditions are prevalent, highly debilitating and have high cost 119 implications to health and social care. These conditions affect patients, their families and 120 society at large, impacting approximately 20% of the global population^[1]. The prevalence of 121 pain conditions among females of all ages appears to be increasing^[2]. Complexities around 122 diagnosis and treatment of chronic pain conditions have meant that there is a paucity of 123 standardised clinical guidelines that could potentially improve the clinical practice landscape, 124 globally.

125

126 Convalescent periods for many chronically ill patients can be protracted and daunting. This 127 may be especially true where pain medication has been used in the long term ^[3]. Long-term 128 exposures to chronic pain coincide with mental health and wellbeing issues, exacerbating 129 patient-reported outcomes such as sleep disturbances, depression, dependence and 130 morbidities such as myalgia, lethargy and fatigue^[4]. Better understanding of long-term 131 implications requires consideration of "life-course approaches" and at present, this could 132 evolve further within pain medicine epidemiology ^[5].

133

134 The increase in chronic pain conditions contributes to higher healthcare costs towards 135 clinical management of patients, and also reduced levels of productivity for employers ^[6]. 136 This may be partly due to increases in opioid use within this population of patients, often 137 reducing their capacity to conduct normal working hours. Current clinical guidelines 138 recommend non-invasive pain management options as a first-line treatment among non-139 cancer patients in particular, although overdose, dependency and mortality due to opioid use has consistently increased over time^[7]. It was reported that global opioid use has doubled 140 between 2011 and 2003 to 2011 and 2013 to 7.35 billion daily doses per year^[6]. These 141 142 figures were attributed to North America and Europe largely and could reflect the increase in the population ^[7]. Attrition data with regards to differentiating those with recreational use and 143 144 those on medical prescription for a long-term conditions during this period remains scarce.

145

146 The World Health Organisation's (WHO) analgesic framework could be a useful model to 147 consider while determining the rates and prevalence of pain management methods including 148 opioid use among those with and without cancer pain^[8]. It is particularly important to develop 149 evidence-based guidelines specific to each condition, with flexible pain medication use as a 150 single regimen or a combination of treatments that could improve the overall quality of life of 151 these patients^[9]. The premise to increase the strength and frequency of pain medications is 152 in general based on disease burden i.e. progression of symptoms and patients reported 153 symptoms. Pain inferences in particular could play a vital role in the use of analgesics ^[10]. 154 The primitive consciousness and the link to mental health is yet another factor that would 155 exacerbate pain medication use. Additional approaches, for example using a cognitive 156 behavioural-based therapeutic protocol with pharmaceutical management can benefit 157 patients ^[10]. However, the benefits of these approaches remain unclear due to a paucity of 158 evidence from both clinical trials and real-world study evidence. We have designed the POP 159 project as the initial step to conduct exploratory work on pharmaceutical management of 160 chronic pain. With the rising need for comparative effectiveness research, increasingly more systematic reviews focus on evaluating the relative efficacy and acceptability of drugs and 161 therapeutic interventions^[11]. However, some of the interventions for long-term conditions are 162

not available for clinical practice and there are several options with varying efficacy even
 within a specific class of interventions^[12].

165

166 Methods

167

168 We developed a wide systematic methodology and published this as a protocol with multiple 169 research questions in the first instance in PROSPERO (CRD42021235384). Data from 170 studies meeting the inclusion criteria were extracted and Pairwise Meta-Analysis with 171 random and fixed effects models was carried out. Pooled mean difference (MD) together 172 with 95% confidence intervals (CIs) are reported overall and for sub-groups. By combining 173 the direct and indirect comparisons between different interventions, Network Meta-Analysis 174 was conducted to explore the relative treatment effects among all the drugs included in our 175 analysis.

- 176
- 177 Aims 178

The aims of the study was to explore the prevalence of treatments of effects in chronic painbased on pharmaceutical treatments.

- 181182 Search strategy
- 183

The search strategy used key words of *chronic pain, opioids, acute pain, pain management, opiods, NSAIDs, analgesics* across multiple databases (PubMed, Science direct, ProQuest,
Web of science, Ovid Psych INFO, PROSPERO, EBSCOhost, MEDLINE, ClinicalTrials.gov
and EMBASE).

188

189 Eligibility criteria

190

All randomised controlled clinical trials (RCTs), epidemiology and mixed-methods studies reporting the use of pain medication for non-cancer chronic pain conditions published in English between the 1st January 1990 and 30st April 2022 were included. Opinions, commentaries and editorials were excluded.

195

196 {PRISMA diagram}

197 198 Data extraction

199 200 Po

200 Participants included in the study populations were those who were experiencing chronic 201 pain. All studies reporting drug efficacy associated with chronic pain were extracted by way 202 of the interventions, measures of tool and numeric results. An extraction template specific to 203 the objectives of the study was developed to gather a wider dataset with vital data for 204 statistical analysis. The number of studies was the number of independent RCTs included in 205 analysis, however sub-studies were extracted from the same clinical trials with different 206 duration periods. The results of different stages in one designed study can be regarded as 207 new sub-studies as new rows in data analysis.

208 Data was extracted by two investigators and any disputes for eligibility was discussed and 209 agreed with the Chief Investigator of the study. All studies included within the analyses were 210 independently reviewed.

- 211
- 212

213214 Outcome measures

215

Outcomes were reported as mean, median, standard deviation and confidence intervals. Mean and standard deviation were extracted as the main outcomes including pre-treatment pain scores at baseline, post-treatment pain scores and pain score changes of each group.

Multiple pain assessments for confirming a clinical diagnosis, severity and progression of chronic pain were identified. These include VAS (visual analogue scale, 0-10 or 0-100), NRS (11-point numeric rating scale, 0-10), BPI (Brief Pain Inventory interference scale, 0-10), MPQS (McGill Pain Questionnaire-Short Form (Sensory and Affective subscales, VAS intensity measure, 0-10), VRS (verbal rating scale, 0-10), NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index, pain scores, 0-21), PI (pain intensity on a 20point scale, 0-20).

226

As most widely used tools for assessing pain such as VAS, NRS, VRS, use a 11-point numeric rating scale from 0 to 10, the following standardisation formula was used to unify all pain scores into the same scale:

230

Scaled Pain Score = Original Pain Score *
$$\frac{10}{\text{Scale Range}}$$

231

As all outcomes of interest were continuous, the calculation based on pain scores was performed by using mean differences (MD) with a 95% confidence interval (CI) to report the effects between the group comparisons.

- 235236 Exposures
- 237

The exposures of interest were selected based on the key features of pharmacological management used to treat non-cancer chronic pain, including and not limited to a pain condition being the primary or the secondary condition. Neurological and psychological symptoms leading up to the use of pharmaceutical use within the included population were also considered.

- 243
- 244 Statistical analysis plan

A meta-analysis, pairwise meta-analysis (PMA) and Network meta-analysis (NMA) were used to compare all treatments used in managing chronic pain. The fundamental difference between them is that PMA produces only one estimate of pooling effects from the selected pair of interventions, while NMA produces multiple comparative estimates of pooling effects by connecting all alternative interventions.^[14]

251

252 We incorporated direct and indirect treatment comparisons within the NMA providing greater statistical precision compared to a PMA ^[20]. Rankings of a set of drugs or combined 253 254 interventions for assessing chronic pain with respect to their efficacy was calculated based 255 on the netowkr models. Homogeneity and Consistency were tested to see if the assumptions 256 in NMA were violated. NMA was conducted with 2-arm and multi-arm studies including more 257 types of Pharmaceutical interventions. PMA was conducted with 2-arm studies with the 258 placebo as the control group while a pharmaceutical intervention as the experimental group. 259 The overall pharmaceutical efficacy of extracted studies was produced by pooling all

treatment effects. PMA was also used on studies with the same drug as the treatment groupto see the specific drug efficacy.

262

263 I² and p-value were commonly used to detect statistical heterogeneity. A value of I² larger than 50% with a much smaller p-value indicates strong heterogeneity. Correspondingly, I^2 264 265 less than 50% with a large p-value indicates fairly weak heterogeneity ^[16]. A random effects 266 model was chosen when there was high heterogeneity, whereas a fixed effects model was used if weak or no heterogeneity was detected ^[17]. Due to the presence of high 267 268 heterogeneity, subgroup analyses were carried out to identify the sources. To assess the 269 robustness of the pooled results within the PMA, a sensitivity analysis was completed. 270 Publication bias was evaluated with funnel plots and Egger tests. The statistical analyses 271 were produced by R and packages were used to provide outputs in compliance with best 272 practice and reporting guidelines ^[18].

- 273
- 274

275 **Results**276

Of the 119 systematically included studies (Table 1) with 17,708 participants, 24 were used
in the meta-analysis. The 24 studies were placebo-controlled RCTs with a primary endpoint
of efficacy. Of the 119 studies, 34 were used in the NMA to build a connected network.

280

281 Opioids (Table 2) were most commonly tested in 32 (26.89%) studies enrolling 5518 282 (31.16%) participants, where *Morphine*, *Oxycodone* and *Fentanyl* were prominently tested. 283 Lidocaine, Naloxone and Gabapentin were the most frequently tested non-opioid drugs for 284 chronic pain. The most common pain among chronic pain patients were lower back pain, 285 which was explored in 26 (21.85%) studies with a pooled sample of 4626 (26.12%) while 13 286 studies reported chronic back pain among 1068 (6.03%) participants. The following pain 287 types are post-surgical pain and neuropathic pain with 19 (15.97%) and 10 (8.4%) studies 288 involved to test the efficiency of NSAID drugs on patients.

289

290 Meta-analysis of mean difference of pain scores were applied to 24 studies with a sample of 291 2546 participants, producing a pooled mean difference (MD) of -0.89 (95% CI = [-1.31, -292 0.47]). There was a significant difference between chronic pain scores of patients taking 293 NSAIDs compared to a placebo. Averagely, 0.89 point (0-10 scale) of pain reduction was 294 observed based on the random effects model. A significant statistical drug efficiency was 295 observed with BTX-A and Ketamine. A negative pooled mean difference was determined 296 between BTX-A and Ketamin versus a placebo with a pain reduction of 0.98 -1.26 based on 297 a -10 scale, respectively. Similar statistical results were not obserbed with other drugs in 298 comparison to a placebo.

299

With the common comparator as "*placebo*", the connected network included 34 studies, 52 pairwise comparisons, 32 interventions and 29 study designs. Gabapentin had a significant mean difference equaling to -1.49 (95% CI = [-2.76, -0.23], p-value < 0.05). Most interventions had a negative mean difference compared to a *placebo*, but a 95% CI covering 0 indicated insignificant effects for reducing pain. The results within the network were more conservative with the combination of direct and indirect evidence indicating most pharmaceutical interventions selected might have benefited from the "*placebo effect*".

307

308 309

Table 1 Characteristics of the studies included in systematic review

Stu dy ID	Authors	Public ation Year	Study Type	Pain Type	Interventi on	Sam ple Size	Mean Age	Count ry	Includ ed for MA	Includ ed for NMA
1	Weizman et al	2018	P-C,RCT	Chronic-pain	тнс	17	33.3	Israel	No	No
2	Krebs et al.	2018	RCT	Back,Arthritis,Chr onic-pain	Opioid	240	56.8	USA	No	No
3	AbdelHaf eez et al.	2019	Double- blind,P- C,RCT	Chronic-pain	Gabapenti n	60	32.7	UK	Yes	Yes
4	Bushey et al.	2021	RCT	Chronic-pain Opioid 241 37 USA No		No	No			
5	Bruehl et al.	2021	Double- blind,P- C,RCT,Cross over	Low- back,Chronic-pain	Morphine + Naloxone	191	36.5	USA	No	No
6	Worley et al.	2015	RCT	Chronic-pain	Buprenorp hine/Nalox one	149		USA	No	No
7	Dindo et al.	2018	Single- blinded,RCT	Postsurgical,Chro nic-pain	ACT	76	62.2	USA	No	No
8	Hruscha k et al.	2019	Single- blinded,RCT	Chronic-pain	IPGT	30	53.9	USA	No	No
9	Azevedo et al.	2013	Open Johel D	Chronic-pain	Opioid	2213	45	Portug al	No	No
10	Gudin et al.	2020	C,Uncontrolle	back,Noncancer,C hronic-pain	NKTR-181	402	52	USA	No	No
11	Stahl et al.	2019	RCT	Low- back,Chronic-pain	Venlafaxin e	209	69.6	USA	No	No
12	Schliess bach et al.	2018	Double- blind,P- C,RCT	Low- back,Chronic-pain	lmipramin e	50	54.4	Switze rland	No	No
13	Mohame d et al.	2016	Double- blind,RCT	PostsurgicalNeuro pathic,Cancer,Chr onic-pain	Morphine	90	50.43	Egypt	No	No
14	Schliess bach et al.	2018	P-C,RCT	Low- back,Chronic-pain	Oxycodon e+Imipram ine+Cloba zam	98	55	Switze rland	No	Yes
15	Hermans et al.		Double- blind,P- C,RCT,Cross over	Arthritis,Chronic- pain	Naloxone	31	39.8	Belgiu m	No	No
16	Todorov et al.	2005		Chronic-pain	Gabapenti n+Tiagabi ne	91	42	USA	No	Yes
17	Sadatsu ne et al.		Double- blind,P- C,RCT	Chronic-pain	Gabapenti n	40	51.5	Brazil	No	No
18	Edwards et al.	2016	RCT	Back,Chronic-pain	Opioid	31	49	USA	No	No
19	Katz et al.	2011	Double- blind,P- C,RCT	Low- back,Chronic-pain	Naproxen +Tanezum ab	129	52.1	USA	No	No
20	Hayek et al.	2021	Double- blind,RCT,Cro ssover	Chronic-pain	Opioid+Bu pivacaine	16	63.1	USA	No	No
21	Schliess bach et al.	2017	Double- blind,P- C,Crossover	Back,Chronic-pain	Clobazam	49	54.3	Switze rland	No	Yes
22	Bruehl et al.	2004	Double- blind,P- C,RCT,Cross over	Low- back,Noncancer,C hronic-pain	Opioid	28	37.3	USA	No	No
23	Kim et al.	2018	Double- blind,RCT	Postsurgical,Chro nic-pain	Nefopam	58	40	South korea	No	No

24	Eisenach et al.	2010	Double- blind,P- C,RCT,Cross	Chronic-pain	Ketorolac	15	44		No	No
25	Rauck et al.	2014	Single- blinded,RCT, Crossover	Chronic-pain	Adenosine /Clonidine	22	44	USA	No	No
26	Buchheit et al.	2019	Double- blind,P- C,RCT	Postsurgical,Chro nic-pain	Valproate	128	57	USA	No	No
27	Papadok ostakis et al.	2005		Back,Chronic-pain	Calcitonin	110	65	Greec e	No	No
28	Gould et al.	2020	Double- blind,4- arm,RCT	Back,Chronic-pain	Desiprami ne	141	51.5	USA	No	Yes
29	Schnitzer et al.	2016	Double- blind,P- C,RCT	Back,Chronic-pain	D- cycloserin e	41	53.2	USA	No	No
30	Nenke et al.	2015	Double- blind,P- C,RCT,Cross over	Low- back,Noncancer,C hronic-pain	Hydrocorti sone	26	71	Austra lia	Yes	Yes
31	Sopata et al.	2015	Double- blind,P- C,RCT	Chronic-pain	Opioid	100	62.1	Polan d	No	No
32	Kendall et al.		Double- blind,P- C,RCT	Postsurgical,Chro nic-pain	Lidocaine	148	48	usa	No	No
33	Hongo et al.	2015	RCT	Back,Chronic-pain	Risedronat e+Elcatoni n	45	70.9	Japan	No	No
34	Amr & Yousef	2010	Double- blind,RCT	Postsurgical,Chro nic-pain	Venlafaxin e+Gabape ntin	150	45	Egypt	No	No
35	Pederse n et al.	2014	Double- blind,RCT	Chronic-pain	Codeine+ Paracetam	58	49	Norwa y	No	No
36	Choi et	2016	Double- blind RCT	Postsurgical,Chro	Lidocaine	90	34	Korea	No	No
37	Bruehl	2014	P-C,RCT	Back,Chronic-pain	Morphine+	50	36.9	USA	Yes	Yes
38	Chrubasi k et al.	2010	Double- blind,P- C.RCT	Chronic-pain	Capsicum	130	48.9	Germ any	No	No
39	Schliess bach et al.	2017	Double- blind,P- C,RCT,Cross over	Back,Chronic-pain	Oxycodon e	50	55	Switze rland	No	Yes
40	Bruehl & Chung	2006	Double- blind,P- C,RCT,Cross	Low- back,Chronic-pain	Naloxone	119	35.1	USA	No	No
41	Bruehl et al.	2013	Double- blind,P- C,RCT,Cross over	Low- back,Chronic-pain	Naloxone+ Morphine	76	37.9	USA	No	No
42	Burns et al.	2017	Double- blind,P- C.RCT	Low- back,Chronic-pain	Naloxone+ Morphine	89	36.9	USA	No	No
43	Eker et al.	2016	Double- blind RCT	Knee,Arthritis,Chr	Lidocaine	52	65.15	Turke v	Yes	Yes
44	Kim et	2015	Double- blind RCT	Cancer,Chronic-	Opioid	49	62	Korea	No	No
45	Kimos et al.	2007	Double- blind,P- C RCT	Chronic-pain	Gabapenti n	50	33.58	Canad a	Yes	Yes
46	Narang et al.	2008	Double- blind,P- C,RCT,Cross over	Chronic-pain	Opioid	30	43.5	USA	No	No
47	Peyton et al.	2017	P-C,RCT	Postsurgical,Chro nic-pain	Ketamine	80	55.3	Austra lia	No	No

48	Katz et al.	2005	P- C,RCT,Cross	Low- back,Chronic-pain	Bupropion	60	49.8		Yes	Yes
49	Hashmi et al.	2012	Double- blind,P- C.RCT	Back,Chronic-pain	Lidocaine	30	51.36	USA	No	No
50	Shimoya ma et al.	2014	Double- blind,P- C,RCT,Cross	Cancer,Chronic- pain	Fentanyl	51	59.1	Japan	No	No
51	Wreje & Brorsson	1995	RCT	Chronic-pain	Sterile water	117	>=25	Swed en	No	No
52	Han et al.	2016	Double- blind,P- C,RCT	Neuropathic,Chro nic-pain	BTX-A	40	53.1	korea	Yes	Yes
53	Rauck et al.	2014	Double- blind,P- C.RCT	Chronic-pain	Hydrocodo ne	510	50.4	USA	No	No
54	Kim et al.	2010	Double- blind,P- C.RCT	Postsurgical,Chro nic-pain	Pregabalin	94	39	Korea	No	No
55	Lee et	2019	RCT	Chronic-pain	BTX-A	60	50.9	Korea	No	No
56	Rashiq et al.	2003	Double- blind,P- C,RCT,Cross over	Low- back,Chronic-pain	Fentanyl	28	54		Yes	Yes
57	Kang et al.	2020	Double- blind,P- C,RCT	Postsurgical,Chro nic-pain	Ketamine	168	50.8	korea	No	No
58	Lipton et al.	2021	P-C,RCT	Chronic-pain	Erenumab	955	41.1	Canad a-13*	No	No
59	Williams on et al.	2014	P-C,RCT	Low- back,Knee,Arthriti s.Chronic-pain	Duloxetine	780	63.2	Canad a	No	No
60	Guo et al.	2020	RCT	Low- back.Chronic-pain	Celecoxib Eperisone	150	36	China	No	No
61	Damjano v et al.	2018	Double- blind,P- C,RCT	Chronic-pain	ACS	32	59		No	No
62	Abd- Elshafy et al.	2019	Double- blind,RCT	Postsurgical,Chro nic-pain	Bupivacai ne	60	35	Egypt	No	Yes
63	Levesqu e et al.	2021	Double- blind,RCT	Chronic-pain	BTX+Ropi vacaïne	80	53.1		No	No
64	Maher et al.	2018	P-C,RCT	Chronic-pain	Ketamine	79	50.32	USA	No	No
65	Barry et al.	2019	RCT	Back,Chronic-pain	Methadon e	40	37.7	USA	No	No
66	Shokeir & Mousa	2015	Double- blind,P- C,RCT	Chronic-pain	Bupivacai ne	60	32.8	Egypt	Yes	Yes
67	Scudds et al.	1995	Double- blind,P- C,RCT	Chronic-pain	Lidocaine	61	46.1	Canad a	No	No
68	Gimbel et al.	2016	Double- blind, P- C, RCT	Low- back,Chronic-pain	Buccal buprenorp hine	510	52.8	USA	No	No
69	Matsuok a et al.	2019	P-C,RCT	Neuropathic,Canc er,Chronic-pain	Duloxetine	70	64.7	Japan	No	No
70	Yurekli et al.	2008	Double- blind,P- C,RCT	Chronic-pain	Sodium valproate	70	40	Turke y	Yes	Yes
71	Maarrawi et al.	2018	Double- blind,P- C,RCT	Chronic-pain	Amitriptyli ne	112	43.54	Leban on	Yes	Yes
72	Li et al.	2018	Double- blind,RCT	Postsurgical,Chro nic-pain	Ropivacai ne+Dexam ethasone	52	62	China	No	No
73	Almog et al.	2020	Double- blind,3- arm,RCT,Cro	Chronic-pain	THC	27	48.3	Israel	No	No

			ssover							
74	Wylde et al.	2015	Double- blind,RCT	Postsurgical,Knee ,Chronic-pain	Bupivacai ne	273	66	UK	No	No
75	Matsuka wa et al.	2020	RCT	Chronic-pain	Cernitin+T adalafil	100	65.9	Japan	No	No
76	Haddad et al.	2018	Double- blind,P- C,RCT,Cross over	Chronic-pain	Apomorphi ne	35	56.2	Israel	No	No
77	de Vries et al.	2016	Double- blind,P- C,RCT	Postsurgical,Chro nic-pain	THC	65	52.2	Nether lands	Yes	Yes
78	Urquhart et al.	2018	Double- blind,RCT	Low- back,Chronic-pain	Amitriptyli ne	146	53.5	Austra lia	No	Yes
79	Lichtman et al.	2018	Double- blind,P- C,RCT	Cancer,Chronic- pain	Nabiximol s	397	59.2	Belgiu m-12*	No	No
80	Schiphor st et al.	2014	Trible-Blind,P- C,RCT	Low- back,Chronic-pain	Acetamino phen/Tram adol	50	42	Nether lands	No	No
81	Cardena s et al.	2002	RCT	Chronic-pain	Amitriptyli ne	84	41	USA	Yes	Yes
82	Arnold et al.	2012	Double- blind,P- C,RCT	Chronic-pain	Milnacipra n	1025	49.1	USA	No	No
83	Wasan et al.	2005	Double- blind,P- C,RCT,Cross over	Low- back,Chronic-pain	Morphine	20	44.2	USA	No	No
84	Baron et al.	2014	Double- blind,RCT	Neuropathic,Low- back,Chronic-pain	Tapentado I/Pregabali n	445	56.3	Germ any	No	No
85	Portenoy et al.	2007	Double- blind,P- C,RCT	Low- back,Chronic-pain	Fentanyl	77	48.9	USA	No	No
86	Likar et al.	1997	Double- blind,RCT,Cro ssover	Arthritis,Chronic- pain	Morphine	21	68	Austri a	No	No
87	Schwartz man et al.	2009	Double- blind,P- C,RCT	Chronic-pain	Ketamine	20	38	USA	Yes	Yes
88	Chu et al.	2012	Double- blind,P- C,RCT	Back,Chronic-pain	Morphine	139	44	USA	Yes	Yes
89	Sandrini et al.	2011	Double- blind,P- C,RCT	Chronic-pain	BoNTA	56	48.5	USA	No	No
90	Mahowal d et al.	2009	Single- blinded,P- C,RCT	Arthritis,Chronic- pain	BoNTA	40	>=48	USA	Yes	Yes
91	Loftus et al.	2010	Double- blind,P- C,RCT	Back,Chronic-pain	Ketamine	102	51.7	Leban on /USA	Yes	Yes
92	Lehmann et al.	1997	P-C,RCT	Postsurgical,Chro nic-pain	Fentanyl	29	44.15	USA	No	No
93	Kahlenb erg et al.	2017	P-C,RCT	Chronic-pain	Celecoxib	98	34.2	USA	Yes	Yes
94	Silberstei n et al.	2009	Double- blind,P- C,RCT	Chronic-pain	Topiramat e	306	38.2	USA	No	No
95	Burgher et al.	2011	Double- blind,RCT	Low- back,Chronic-pain	Lidocaine	26	44.1	USA	No	No
96	McClean e	1999	Double- blind,P- C,RCT,Cross over	Neuropathic,Chro nic-pain	Phenytoin	20	40	Irelan d	Yes	Yes
97	Naliboff et al.	2011	2-arm,RCT	Chronic-pain	Opioid	135	52.7	USA	No	No

98	Booth et al.	2017	P-C,RCT	Postsurgical,Chro	Morphine	74	28	USA	No	Yes
99	Lee et al.	2006	Single- blinded,RCT	Chronic-pain	Rowatinex /lbuprofen	50	44.2	Korea	No	No
10 0	Levendo glu et al.	2004	Double- blind,P- C,RCT,Cross over	Neuropathic,Chro nic-pain	Gabapenti n	20	35.9	Turke y	Yes	Yes
10 1	Yousef & Alzeftaw y	2018	Double- blind,RCT	Chronic-pain	Opioid	100	53.44	Egypt	No	Yes
10 2	Yelland et al.	2009	Double- blind,P- C,RCT,Cross over	Neuropathic,Chro nic-pain	Gabapenti n	73	57.8	Austra lia	No	No
10 3	Yucel et al.	2004	Double- blind,P- C,RCT	Neuropathic,Chro nic-pain	Venlafaxin e	55	48.94	Turke y	No	No
10 4	Hudson et al.	2021	Double- blind,P- C,RCT	Knee,Arthritis,Chr onic-pain	Nortriptylin e	205	64.4	New Zeala nd	Yes	Yes
10 5	Rauck et al.	2006	Double- blind,P- C,RCT	Chronic-pain	Ziconotide	220	52.5	USA	No	No
10 6	Sandner- Kiesling et al.	2010	Double-blind	Noncancer,Chroni c-pain	Naloxone+ Oxycodon e	379	56.2	Austri a/Ger many	No	No
10 7	Wang et al.	2017	RCT	Chronic-pain	Diosmin	300	41	China	No	Yes
10 8	Hawley et al.	2020	Double- blind,P- C,RCT,Cross over	Cancer,Chronic- pain	Lidocaine	25	53.76	Canad a	No	No
10 9	Mathieso n et al.	2017	Double- blind,P- C,RCT	Chronic-pain	Pregabalin	209	66	Austra lia	No	No
11 0	Wetzel et al.	2015	Double- blind,P- C,RCT,Cross over	Low- back,Noncancer,C hronic-pain	Nonopioid analgesic drugs	36	55	Austri a	No	No
11 1	Khan et al.	2019	P-C,RCT	PostsurgicalNeuro pathic,Cancer,Chr onic-pain	Lidocaine+ Pregabalin	100	55.2	Canad a	No	No
11 2	Clarke et al.	112	Double- blind,RCT	Postsurgical,Chro nic-pain	Gabapenti n	126	58.9	Canad a	Yes	Yes
11 3	Ma et al.	113	Double- blind,P- C,RCT	Chronic-pain	Oxycodon e	116	58.2	China	Yes	Yes
11 4	J. H. Lee & C. S. Lee	114	Double- blind,P- C,RCT	Low- back,Chronic-pain	TA-ER	245	59.9	Korea	No	No
11 5	lmamura et al.	2016	Trible- Blind,RCT	Low- back,Chronic-pain	Lidocaine	378	48.26	Brazil	No	No
11 6	Baron et al.	2015	RCT	Neuropathic,Low- back,Chronic-pain	Tapentado I	258	58.1	Germ any	No	No
11 7	Kim et al.	2017	Double- blind,RCT	Postsurgical,Canc er,Chronic-pain	Lidocaine+ Magnesiu m	126	48.7	Korea	Yes	Yes
11 8	lwamura et al.	2015	RCT	Chronic-pain	Eviprostat	100	50.1	Japan	No	No
11 9	Zhang et al.	2021	Double- blind,P- C,RCT	Chronic-pain	Ningmitai	120	33.7	China	No	No

310 Canada-13*: "Canada-13" was used as the group of 13 countries: "Canada, Austria, Belgium, Czech Republic, Finland,

311 Germany, Poland, Slovakia, Sweden, the United Kingdom, Turkey, the Netherlands and USA".

Belgium-12*: "Belgium-12" was used as the group of 12 countries: "Belgium, Bulgaria, Czechia, Germany, Hungary, Latvia,

313 Lithuania, Poland, Puerto Rico, Romania, United Kingdom, United States".

314

315	
316	Table 2
317	

Table 2 Summary of drug and pain types included in systematic review

Summary of drug and pain types included in studies systematic review Classes Drug types Studies (Number, %) Participants (Number, %) Oxycodone 4 (3.36%) 643 (3.63%) Fentanyl 4 (3.36%) 185 (1.04%) Methadone 1 (0.84%) 40 (0.23%) Morphine 9 (7.56%) 750 (4.24%) Buprenorphine 2 (1.68%) 659 (3.72%) Codeine 1 (0.84%) 58 (0.33%) Other Opioids 11 (9.24%) 3183 (17.97%) Naloxone 8 (6.72%) 1084 (6.12%) Gabapentin 8 (6.72%) 1084 (6.12%) Lidocaine 10 (8.4%) 1036 (5.85%) Ketamine 5 (4.2%) 449 (2.54%) Amitriptyline 3 (2.52%) 342 (1.93%) Bupivacaine 4 (3.36%) 409 (2.31%) THC 3 (2.52%) 109 (0.62%) Others 54 (45.38%) 9251 (52.24%) Raticipants (Number, %) Participants (Number, %) Participants (Number, %) Descurrence 54 (45.38%) 9251 (52.24%)								
Classes	Drug types	Studies (Number, %)	Participants (Number, %)					
	Oxycodone	4 (3.36%)	643 (3.63%)					
	Fentanyl	Studies (Number, %) Participants (Number, %) 4 (3.36%) 643 (3.63%) 4 (3.36%) 185 (1.04%) 1 (0.84%) 40 (0.23%) 9 (7.56%) 750 (4.24%) 2 (1.68%) 659 (3.72%) 1 (0.84%) 58 (0.33%) 11 (9.24%) 3183 (17.97%) 8 (6.72%) 1084 (6.12%) 8 (6.72%) 610 (3.44%) 10 (8.4%) 1036 (5.85%) 5 (4.2%) 342 (1.93%) 4 (3.36%) 409 (2.31%) 3 (2.52%) 109 (0.62%) 54 (45.38%) 9251 (52.24%) Studies (Number, %) Participants (Number, %) 19 (15.97%) 1987 (11.22%) 10 (8.4%) 1171 (6.61%) 26 (21.85%) 4626 (26.12%) 8 (6.72%) 908 (5.13%) 13 (10.92%) 1068 (6.03%) 4 (3.36%) 1310 (7.4%) 7 (5.88%) 1369 (7.73%) 4 (3.36%) 300 (1.69%) 42 (35.29%) 8578 (48.44%)	185 (1.04%)					
	Methadone	1 (0.84%)	40 (0.23%)					
Opioids 32 (26 89%)	Morphine	9 (7.56%)	750 (4.24%)					
02 (20.0070)	Buprenorphine	2 (1.68%)	659 (3.72%)					
	Codeine	1 (0.84%)	58 (0.33%)					
	Other Opioids	11 (9.24%)	3183 (17.97%)					
	Naloxone	8 (6.72%)	1084 (6.12%)					
	Gabapentin	8 (6.72%)	610 (3.44%)					
	Lidocaine	10 (8.4%)	1036 (5.85%)					
Nononicido	Ketamine	Studies (Number, %) Participants (Number, %) 4 (3.36%) 643 (3.63%) 4 (3.36%) 185 (1.04%) 1 (0.84%) 40 (0.23%) 9 (7.56%) 750 (4.24%) e 2 (1.68%) 1 (0.84%) 40 (0.23%) 9 (7.56%) 750 (4.24%) e 2 (1.68%) 1 (0.84%) 58 (0.33%) s 11 (9.24%) 3 183 (17.97%) 8 (6.72%) 1084 (6.12%) 8 (6.72%) 610 (3.44%) 10 (8.4%) 1036 (5.85%) 5 (4.2%) 449 (2.54%) 3 (2.52%) 342 (1.93%) 4 (3.36%) 409 (2.31%) 3 (2.52%) 109 (0.62%) 54 (45.38%) 9251 (52.24%) Studies (Number, %) Participants (Number, %) 19 (15.97%) 1987 (11.22%) 10 (8.4%) 1171 (6.61%) 26 (21.85%) 4626 (26.12%) 8 (6.72%) 908 (5.13%) 8 (6.72%) 908 (5.13%) 8 (6.72%) 908 (5.13%)						
Naloxone 8 (6.72%) Gabapentin 8 (6.72%) Lidocaine 10 (8.4%) Ketamine 5 (4.2%) Amitriptyline 3 (2.52%) Bupivacaine 4 (3.36%) THC 3 (2.52%) Others 54 (45.38%)	342 (1.93%)							
	Bupivacaine	4 (3.36%)	409 (2.31%)					
	THC	3 (2.52%)	109 (0.62%)					
	Others	54 (45.38%)	9251 (52.24%)					
Categories	Pain types	Studies (Number, %)	Participants (Number, %)					
	Postsurgical	19 (15.97%)	1987 (11.22%)					
	Neuropathic	10 (8.4%)	1171 (6.61%)					
	Low Back	26 (21.85%)	4626 (26.12%)					
	Cancer	8 (6.72%)	908 (5.13%)					
Chronic Pain	Back (Except Low-Back)	13 (10.92%)	1068 (6.03%)					
	Knee	4 (3.36%)	1310 (7.4%)					
	Arthritis	7 (5.88%)	1369 (7.73%)					
	Pelvic	4 (3.36%)	300 (1.69%)					
	Other Chronic Pain	42 (35.29%)	8578 (48.44%)					

318

319

320 Pairwise Meta-Analysis (PMA)

The PMA included 24 studies with pairwise comparisons between drugs and a placebo. The
experimental and control group comprised of "Amitriptyline", "BTX-A", "Gabapentin",
"Ketamine", "Lidocaine", "Morphine", "Naloxone" and a placebo, respectively. A single study
reported "Fentanyl", "Ningmitai", "THC", and "Oxycodone".

- 326
- 327 PMA for Baseline Pain Score
- 328

The PMA was used to test baseline pain score differences between the experimental and control group in 18 studies which comprised of a total sample of 1,691 participants. The experimental and control groups comprised of 837 and 854 participants, respectively, with a

pooled mean difference (MD) of -0.02 (95% CI = [-0.13, 0.08]). The 95% CI was 0 and therefore, no statistically significant difference between baseline pain scores of two groups. [Figure 1]. A weak statistical heterogeneity of 15% of I^2 (p = 0.26) was determined. This combined with the statistical insignificance indicates the randomisation of was completed accurately and that it is scientifically justifiable to use the post-treatment pain scores directly as the outcomes to evaluate treatment effects.

338

	E	Experimental		Control			
Study	Total	Mean SD	Total	Mean SD	Mean DifferenceMD	95%-CI	Weight
[96] McCleane 1999 [Phenytoin]	20	3.29 3.3900	20	3.59 3.5000	-0.30	[-2.44; 1.84]	0.2%
[81] Cardenas et al. 2002 [Amitriptyline]	44	5.50 1.8000	40	5.00 1.7000	++- 0.50	[-0.25; 1.25]	2.0%
[100] Levendoglu et al. 2004 [Gabapentin]	20	8.50 0.9000	20	8.40 0.7000	+ 0.10	[-0.40; 0.60]	4.4%
[48] Katz et al. 2005 [Bupropion]	44	4.49 1.7000	44	4.49 1.7000	0.00	[-0.71; 0.71]	2.2%
[113] Ma et al. 2007 [Oxycodone]	58	6.82 1.8300	58	6.42 1.3100	0.40	[-0.18; 0.98]	3.3%
[70] Yurekli et al. 2008 [VPA]	40	6.80 1.1000	30	6.10 1.6000	0.70	[0.03; 1.37]	2.5%
[87] Schwartzman et al. 2009 [Ketamine]	9	7.66 0.4000	10	7.73 0.4000	-0.07	[-0.43; 0.29]	8.5%
[90] Mahowald et al. 2009 [IA- BoNT/A]	18	7.60 0.3000	22	7.70 0.3000	-0.10	[-0.29; 0.09]	31.5%
[88] Chu et al. 2012 [Morphine]	48	4.95 1.4700	55	5.02 1.4800	-0.07	[-0.64; 0.50]	3.4%
[37] Bruehl et al. 2014 [Morphine]	50	3.86 2.8900	50	3.32 2.6800	→ 0.54	[-0.55; 1.63]	0.9%
[37*] Bruehl et al. 2014 [Morphine]	50	6.90 6.8800	50	5.80 6.0700	→ 1.10	[-1.44; 3.64]	0.2%
[37] Bruehl et al. 2014 [Naloxone]	50	3.43 2.8900	50	3.32 2.6800	→ 0.11	[-0.98; 1.20]	0.9%
[37*] Bruehl et al. 2014 [Naloxone]	50	6.50 7.1200	50	5.80 6.0700	→ 0.70	[-1.89; 3.29]	0.2%
[30] Nenke et al. 2015 [Hydrocortisone]	7	5.81 1.6100	19	5.81 1.6100	0.00	[-1.40; 1.40]	0.6%
[66] Shokeir & Mousa 2015 [Bupivacaine]	30	7.70 0.4200	30	7.90 1.9600	-0.20	[-0.92; 0.52]	2.1%
[43] Eker et al. 2016 [Lidocaine]	26	7.11 1.1000	26	7.19 1.6000	-0.08	[-0.83; 0.67]	2.0%
[52] Han et al. 2016 [BTX-A]	20	8.51 1.3600	20	7.71 1.3300	0.80	[-0.03; 1.63]	1.6%
[52*] Han et al. 2016 [BTX-A]	20	8.51 1.3600	20	7.71 1.4000	0.80	[-0.06; 1.66]	1.5%
[77] de Vries et al. 2016 [THC]	21	4.00 1.8500	29	5.20 1.7500	-1.20	[-2.22; -0.18]	1.1%
[93] Kahlenberg et al. 2017 [Celecoxib]	50	2.10 2.0600	48	2.30 1.9800		[-1.00; 0.60]	1.7%
[3] AbdelHafeez et al. 2019 [Gabapentin]	30	5.94 0.7300	30	6.09 0.5400	+ -0.15	[-0.47; 0.17]	10.4%
[3*] AbdelHafeez et al. 2019 [Gabapentin]	30	5.94 0.7300	30	6.09 0.5400	+ -0.15	[-0.47; 0.17]	10.4%
[104] Hudson et al. 2021 [Nortriptyline]	102	6.02 1.3500	103	6.12 1.2500	-0.10	[-0.46; 0.26]	8.7%
Common effect model	837		854		0.02	[-0.13; 0.08]	100.0%
Heterogeneity: $I^2 = 15\%$, $\tau^2 = 0$, $p = 0.26$							
					-2 -1 0 1 2		

339

Figure 1. Forest plot for the baseline pain scores of experimental group and control group across 18 studies.

342

343 PMA for drug efficacy between NSAID compared to a placebo

344

This PMA included 24 studies [Figure 2] with 2418 participants, with a MD of -0.89 (95% CI = [-1.31, -0.47]). The experimental and control group comprised of 1219 and 1199, respectively. A significant statistical heterogeneity of 92% of I^2 (p-value <0.01) was identified. Mean difference (MD) was calculated to assess if there is statistically significant difference of post-treatment pain scores between experimental group and control group. The 95% CI was less than 0 which indicated a significant treatment effect with a reduction in pain by 0.89-point (0-10 scale) compared to those who were given a placebo.

352

	E	xperimenta	1	C	ontrol			
Study	Total	Mean SE) Total	Mean	SD	Mean DifferenceMD	95%-CI	Weight
[06] McCleans 1000 [Phanitain]	20	2 12 2 2200	20	2 0 2 2	. EE00		1 2 00: 4 201	2.0%
[90] McCleane 1999 [FileNytoin]	20	4 50 1 0000	40	4.00 3	0000	-0.60	[-2.30, 1.30]	2.0%
[56] Pashig et al. 2002 [Aminiptyme]	28	3 10 2 2000	28	4.00 2	2 1000	0.50	[-0.34, 1.34]	3.5%
[100] Lovendersky et al. 2004 [Cabanantin]	20	3.10 2.2000	20	7 40 0	7000	-0.90	[-2.03, 0.23]	3.170
[100] Levendogiu et al. 2004 [Gabapentin]	20	3.20 1.2000	20	2 40 0	0.7000	-4.20	[-4.01, -3.59]	3.1 %
[46] Kimes et al. 2005 [Bupropion]	25	5 10 2 9000	25	3.42	2500	-0.17	[-0.90, 0.02]	1 00/
[45] Kinos et al. 2007 [Gabapentin]	20	3.10 3.0900	50	5.01 0	0700	1.77	[0.30, 4.90]	2.00/
[70] Vurskli et al. 2007 [Oxycodone]	10	3.24 0.9200	20	4 10 1	6000	-1.77	[-2.11, -1.43]	3.9%
[70] Fullekii et al. 2006 [VFA]	40	6 13 1 0000	10	7.50 0	0000	-0.00	[-1.44, 0.24]	3.5%
[00] Mahawald at al. 2009 [Retainine]	10	4 70 0 7000	20	F 90 0	0000	-1.37	[-2.12, -0.02]	3.0%
[90] Manowald et al. 2009 [IA- BONT/A]	10	4.70 0.7000	22	1 20 2	0000	-1.10	[-1.00, -0.00]	3.0%
[112] Clarke et al. 2009 [Gabapentin]	20	4.10 2.2000	30	4.20 2	0000	-0.10	[-1.20, 1.00]	3.1%
[112] Clarke et al. 2009 [Gabapentin]	50	4.90 2.2000	50	4.20 2	1.9000	0.70	[-0.40, 1.00]	3.1%
[91] Lonus et al. 2010 [Ketamine]	52	3.10 2.4000	50	4.20 2	.4000	-1.10	[-2.03; -0.17]	3.4%
[88] Chu et al. 2012 [Morphine]	40	2.11 1.5900	55	1.25	.9200	0.86	[0.18; 1.54]	3.1%
[37] Brueni et al. 2014 [Morphine]	50	2.42 2.8900	50	3.04 2	2.7500	-0.62	[-1.73; 0.49]	3.2%
[37] Brueni et al. 2014 [Morphine]	50	3.90 5.9900	50	4.80 0	.2900	-0.90	[-3.31; 1.51]	1.7%
[37] Bruehl et al. 2014 [Naloxone]	50	2.94 2.8100	50	3.04 2	2.7500	-0.10	[-1.19; 0.99]	3.2%
[37] Bruehl et al. 2014 [Naloxone]	50	5.30 6.1900	50	4.80 6	5.2900	0.50	[-1.95; 2.95]	1.7%
[30] Nenke et al. 2015 [Hydrocortisone]	1	5.00 2.5300) 19	5.59 2	2.2400	-0.59	[-2.72; 1.54]	2.0%
[66] Shokeir & Mousa 2015 [Bupivacaine]	30	5.40 0.1400	30	7.701	.2600	-2.30	[-2.75; -1.85]	3.9%
[43] Eker et al. 2016 [Lidocaine]	26	2.80 1.3000	26	4.80 2	2.5000	-2.00	[-3.08; -0.92]	3.2%
[52] Han et al. 2016 [BTX-A]	20	6.65 2.0700	20	7.45 1	.6000	-0.80	[-1.95; 0.35]	3.1%
[52*] Han et al. 2016 [BTX-A]	20	6.38 2.7500	20	7.68 2	2.0400	-1.30	[-2.80; 0.20]	2.7%
[77] de Vries et al. 2016 [THC]	21	2.40 2.2800) 29	3.50 2	2.4200	-1.10	[-2.41; 0.21]	2.9%
[93] Kahlenberg et al. 2017 [Celecoxib]	50	4.60 1.9100	48	5.40 1	.9200	-0.80	[-1.56; -0.04]	3.6%
[117] Kim et al. 2017 [Lidocaine]	39	2.40 0.7000) 39	2.90 0	0.7000	-0.50	[-0.81; -0.19]	4.0%
[117] Kim et al. 2017 [Magnesium]	38	2.50 0.6000) 39	2.90 0	0.7000	-0.40	[-0.69; -0.11]	4.0%
[71] Maarrawi et al. 2018 [Amitriptyline]	104	3.34 1.4500	108	6.12 0	0.9200	-2.78	[-3.11; -2.45]	3.9%
[3] AbdelHafeez et al. 2019 [Gabapentin]	30	5.12 0.6700) 30	5.90 0	0.9200	-0.78	[-1.19; -0.37]	3.9%
[3*] AbdelHafeez et al. 2019 [Gabapentin]	30	3.72 0.6900) 30	5.50 1	.1300	-1.78	[-2.25; -1.31]	3.8%
[104] Hudson et al. 2021 [Nortriptyline]	102	3.60 2.3200	103	4.25 2	2.4000	-0.65	[-1.30; -0.00]	3.7%
Random effects model	1199		1219			-0.89	[-1.31; -0.47]	100.0%
Heterogeneity: $I^2 = 92\%$, $\tau^2 = 1.1367$, $p < 0.0$	01							
						-2 -1 0 1 2		

Figure 2. Forest plot for the pain scores of experimental group and control group across 24 studies

testing all NSAID drugs (including some unnamed Opioids drugs).

353 354

355

- 355 356
- 357
- 358

359 Meta-Analyses

360

A statistically low heterogeneity of 0% of I^2 (p-value > 0.5) was identified among studies with BTX-A, Ketamine and Naloxone [Figure 3b and 3d]. BTX-A [Figure 3b] and Ketamine [Figure 3d] indicated statistically significant drug efficacy of -1.07 [-1.51, -0.64] and -1.26 [-1.85, -0.68], respectively. The treatment efficiency compared to the placebo had a 1 point pain reduction within a 0-10 evaluation scale. Ketamine demonstrated optimal efficacy with a 1.26 point pain reduction on average.

367

The PMA for *BTX-A* (Figure 3b) and *Naloxone* (Figure 3g) showed a low heterogeneity as the data was pooled from a single study.

370

Studies on Amitriptyline, Gabapentin, Lidocaine and Morphine had a high heterogeneity and a statistically insignificant drug efficacy (Figure 3a, c, e, f). The mean difference of 95% CI was 0 indicating an insignificant treatment difference between the drugs and placebo based on the random effects model.

- 375
- 376

	E	Experi	mental		c	Control				
Study	Total	Mean	SD	Total	Mean	SD	Mean Differen	ceMD	95%-CI	Weight
[81] Cardenas et al. 2002 Other_CP [41-50]	44	4.50	1.9000	40	4.00	2.0000	1 🛲	0.50	[-0.34; 1.34]	49.3%
[71] Maarrawi et al. 2018 Other_CP [41-50]	104	3.34	1.4500	108	6.12	0.9200		-2.78	[-3.11; -2.45]	50.7%
Random effects model Heterogeneity: $l^2 = 98\%$, $\tau^2 = 5.2742$, $p < 0.01$	148			148				-1.16	[-4.38; 2.05]	100.0%
							-4-2024			

Figure 3a. Forest plot for drug efficiency of Amitriptline.

Experimental Control Mean DifferenceMD 95%-CI Weight Study **Total Mean** SD Total Mean SD -1.10 [-1.60; -0.60] 77.1% [90] Mahowald et al. 2009 Arthritis [61-71] 18 4.70 0.7000 22 5.80 0.9000 [52] Han et al. 2016 Neuropathic [51-60] 20 6.65 2.0700 20 7.45 1.6000 -0.80 [-1.95; 0.35] 14.4% [52*] Han et al. 2016 Neuropathic [51-60] 20 6.38 2.7500 20 7.68 2.0400 -1.30 [-2.80; 0.20] 8.4% Common effect model 62 -1.07 [-1.51; -0.64] 100.0% 58 Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, p = 0.85Г -4-2024

Figure 3b. Forest plot for drug efficiency of BTX-A.

381 382 383

		Experi	mental		0	Control			
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	eMD 95%-	CI Weight
[100] Levendoglu et al. 2004 Neuropathic [<=40]	20	3.20	1.2000	20	7.40	0.7000	= I]	4.20 [-4.81; -3.5	9] 17.5%
[45] Kimos et al. 2007 Other_CP [<=40]	25	5.10	3.8900	25	2.43	4.3500		2.67 [0.38; 4.9	6] 13.8%
[112] Clarke et al. 2009 Postsurgical [51-60]	38	4.10	2.2000	38	4.20	2.9000	+ -	0.10 [-1.26; 1.0	6] 16.6%
[112] Clarke et al. 2009 Postsurgical [61-71]	38	4.90	2.2000	38	4.20	2.9000	-	0.70 [-0.46; 1.8	6] 16.6%
[3] AbdelHafeez et al. 2019 Other_CP [<=40]	30	5.12	0.6700	30	5.90	0.9200	-	0.78 [-1.19; -0.3	7] 17.7%
[3*] AbdelHafeez et al. 2019 Other_CP [<=40]	30	3.72	0.6900	30	5.50	1.1300	-	1.78 [-2.25; -1.3	1] 17.7%
Random effects model Heterogeneity: $l^2 = 96\%$ $r^2 = 4.6585$, $n < 0.01$	181			181				0.72 [-2.51; 1.0	7] 100.0%
There is generally. 7 = 50.0, 1 = 4.0000, p = 0.01							-4-2024		

384 385 386

Figure 3c. Forest plot for drug efficiency of Gabapenin.

	I	Experir	nental		0	Control				
Study	Total	Mean	SD	Total	Mean	SD	Mean Differe	nceMD	95%-C	Weight
[87] Schwartzman et al. 2009 Other CP [<=40]	9	6.13	1.0000	10	7.50	0.6000	=1	-1.37	[-2.12; -0.62	60.6%
[91] Loftus et al. 2010 Back [51-60]	52	3.10	2.4000	50	4.20	2.4000	+	-1.10	[-2.03; -0.17	39.4%
Common effect model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.66$	61			60				-1.26	[-1.85; -0.68] 100.0%
							-4-202	4		

387 388 389

Figure 3d. Forest plot for drug efficiency of Ketamine.

Study	l Total	Experi Mean	mental SD	Total	(Mean	Control SD	Mean Differen	ceMD	95%-C	l Weight
[43] Eker et al. 2016 Arthritis [61-71] [117] Kim et al. 2017 Postsurgical [41-50]	26 39	2.80 2.40	1.3000 0.7000	26 39	4.80 2.90	2.5000 0.7000		-2.00 -0.50	[-3.08; -0.92 [-0.81; -0.19] 43.8%] 56.2%
Random effects model Heterogeneity: l^2 = 85%, τ^2 = 0.9597, p < 0.07	65 1			65			-4 -2 0 2 4	-1.16	[-2.62; 0.30] 100.0%

390 391

Figure 3e. Forest plot for drug efficiency of Lidocaine.

	E	xperimenta	al		Control				
Study	Total	Mean SI	D Total	Mean	SD	Mean Differen	ceMD	95%-CI	Weight
[88] Chu et al. 2012 Back [41-50]	48	2.11 1.590	0 55	1.25	1.9200	-	0.86	[0.18; 1.54]	46.1%
[37] Bruehl et al. 2014 Back [<=40]	50	2.42 2.890	0 50	3.04	2.7500	-	-0.62	[-1.73; 0.49]	37.0%
[37*] Bruehl et al. 2014 Back [<=40]	50	3.90 5.990	0 50	4.80	6.2900		-0.90	[-3.31; 1.51]	16.9%
Random effects model	148		155			-	0.01	[-1.18; 1.21]	100.0%
Heterogeneity: $I^2 = 67\%$, $\tau^2 = 0.6853$, p	= 0.05								
						-4-2024			
						-4-2024			

Figure 3f. Forest plot for drug efficiency of Morphine.

	E	Experim	ental		C	ontrol				
Study	Total	Mean	SD	Total	Mean	SD	Mean Differen	ceMD	95%-CI	Weight
[37] Bruehl et al. 2014 Back [<=40]	50	2.94 2	.8100	50	3.04 2	2.7500	*	-0.10	[-1.19; 0.99]	83.4%
[37*] Bruehl et al. 2014 Back [<=40]	50	5.30 6	1900	50	4.80 6	6.2900		0.50	[-1.95; 2.95]	16.6%
Common effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.66$	100			100			· · + + · · ·	-0.00	[-1.00; 0.99]	100.0%
,							-4-2024			

Figure 3g. Forest plot for drug efficiency of Naloxone.

402 Opioids drugs

404 A meta-analysis was conducted with 4 studies with Opioids [Figure 4]. A pooled MD of -0.65 405 and a 95% CI [-1.67, 0.37] was determined indicating an insignificant treatment effect of 406 opioids drugs compared to a placebo. A statistically sginficant heterogeneity of 92% of I^2 (p-407 value < 0.01) was identified.

		Experime	ental		(Control					
Study	Total	Mean	SD	Total	Mean	SD	Mean Differen	ceMD	95	5%-CI	Weight
[56] Rashiq et al. 2003 Low-back [Fentanyl]	28	3.10 2.	2000	28	4.00	2.1000		-0.90	[-2.03;	0.23]	20.0%
[113] Ma et al. 2007 Other_CP [Oxycodone]	58	3.24 0.	9200	58	5.01	0.9700	H	-1.77	[-2.11; -	1.43]	25.6%
[88] Chu et al. 2012 Back [Morphine]	48	2.11 1.	5900	55	1.25	1.9200	-	0.86	[0.18;	1.54]	23.6%
[37] Bruehl et al. 2014 Back [Morphine]	50	2.42 2.	8900	50	3.04	2.7500		-0.62	[-1.73;	0.49]	20.1%
[37*] Bruehl et al. 2014 Back [Morphine]	50	3.90 5.	9900	50	4.80	6.2900		-0.90	[-3.31;	1.51]	10.7%
Random effects model Heterogeneity: $I^2 = 92\%$, $\tau^2 = 1.0251$, $\rho < 0.01$	234			241				-0.65	[-1.67;	0.37]	100.0%
							-4-2024				

Figure 4. Forest plot for drug efficiency of Opioids drugs*.

423 Network Meta-analysis (NMA)

424

A NMA [Figure 5] was completed for 34 studies. The nodes correspond to each intervention included within the network where the interventions with direct comparisons are linked with a line. The thickness of lines corresponds to the number of trials evaluating the comparison. A connected network was built based on the *placebo* which was mostly *Tolterodine* based on the original studies. The evaluations between interventions were supported by direct comparison and indirect comparison

- 431
- 432

Opioids drugs*: including Fentanyl, Oxycodone, Morphine and other unnamed Opioids drugs.



433434 Figure 5 Network plot where Placebo was the reference group with 34 studies and 32 interventions.

- 435
- 436
- 437
- 438
- 439

Transformation	Direct	Comparison: other vs 'Placebo'		05% 01
Treatment	Comparisons	(Random Effects Model)	MD	95%-CI
ActivePlacebo	0		-0.30	[-2.28; 1.68]
Amitriptyline	2		-1.24	[-2.77; 0.30]
Botulinum	3		-1.06	[-2.54; 0.42]
Bupivacaine	1		-2.30	[-4.67; 0.07]
Bupivacaine Dexmedetomidine	0 -		-3.30	[-6.63; 0.03]
Bupropion	1		-0.17	[-2.62; 2.28]
CBT Placebo	0		-0.85	[-4.16; 2.45]
Celecoxib	1		-0.80	[-3.24; 1.64]
Clobazam	0		-1.00	[-4.14; 2.14]
Desipramine	0		-0.88	[-4.20; 2.44]
Desipramine CBT	0		-0.29	[-3.61; 3.02]
Diosmin	0		-2.30	[-5.36; 0.75]
Fentanyl	1		-0.90	[-3.48; 1.68]
Gabapentin	4		-1.49	[-2.76; -0.23]
GPN_Placebo	1		-0.10	[-2.69; 2.49]
Hydrocortisone	1		-0.59	[-3.74; 2.56]
Imipramine	0		-0.20	[-3.35; 2.95]
Ketamine	2		-1.24	[-2.99; 0.51]
Lidocaine	2		-1.18	[-2.91; 0.55]
Magnesium	1		-0.74	[-2.94; 1.46]
Morphine	3		-0.07	[-1.63; 1.49]
Morphine_Acetaminophen	0		-1.57	[-4.57; 1.43]
Naloxone	2		0.45	[-1.48; 2.38]
Nortriptyline	1		-0.65	[-3.06; 1.76]
Oxycodone	1		-1.74	[-3.64; 0.15]
Phenytoin	1		-0.80	[-3.93; 2.33]
Piroxicam	0		-0.80	[-4.28; 2.68]
Placebo	0		0.00	
Placebo_GPN	1		0.70	[-1.89; 3.29]
THC	1		-1.10	[-3.77; 1.57]
Tiagabine	0	_	-1.31	[-3.96; 1.34]
VPA	1		-0.60	[-3.07; 1.87]
		-6 -4 -2 0 2 4 6		

440 441 442

Figure 6 Forest plot for intervention efficiency compared to Placebo in NMA

443 In the network with the placebo as the reference group, Gabapentin [Figure 6] comprised of 444 a MD equaling to -1.49 (95% CI = [-2.76, -0.23], p-value < 0.05) indicating a significant effect 445 on reducing chronic pain and direct comparisons were made using 4 studies [Figure 7a]. The 446 pooled MD of Botulinum and Ketamine were -1.06 and -1.24, respectively. These were 447 similar to the results in the PWA, but their 95% CI was 0 therefore showed insignificant effect 448 on pain reduction compared to a placebo. Most combined interventions had a negative MD 449 compared to a placebo with a 95% CI of 0 indicated statistically insignificant results for 450 reducing pain.

451

Imipramine, Diosimin, Desipramine, Clobazam, Piroxicam and Tiagabine had not been
directly compared to a placebo based on the identified data therefore the comparative
treatment effected between them and a placebo was not possible to complete.

- 455
- 456

N Comparison	umber of Studies	Direct Evidence	12	Random Effects Model	MD	95%-CI
Amitriptyline:Place Direct estimate Indirect estimate Network estimate Prediction interval	bo 2	0.82	98%		-1.22 -1.30 -1.24	[-2.92; 0.48] [-4.88; 2.29] [-2.77; 0.30] [-4.31; 1.83]
Botulinum:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	3	1.00	0%		-1.06 -1.06	[-2.54; 0.42] [-2.54; 0.42] [-4.09; 1.98]
Bupivacaine:Place Direct estimate Indirect estimate Network estimate Prediction interval	bo 1	1.00			-2.30 -2.30	[-4.67; 0.07] [-4.67; 0.07] [-5.95; 1.35]
Bupropion:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	D 1	1.00		<u> </u>	-0.17 -0.17	[-2.62; 2.28] [-2.62; 2.28] [-3.89; 3.55]
Celecoxib:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	1	1.00			-0.80 -0.80	[-3.24; 1.64] [-3.24; 1.64] [-4.51; 2.91]
Fentanyl:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	1	1.00		-	-0.90 -0.90	[-3.48; 1.68] [-3.48; 1.68] [-4.73; 2.93]
Gabapentin:Placeb Direct estimate Indirect estimate Network estimate Prediction interval	4	1.00	97%		-1.49 -1.49	[-2.76; -0.23] [-2.76; -0.23] [-4.41; 1.42]
GPN_Placebo:Place Direct estimate Indirect estimate Network estimate Prediction interval	ebo 1	1.00			-0.10 -0.10	[-2.69; 2.49] [-2.69; 2.49] [-3.94; 3.74]
Hydrocortisone:Pla Direct estimate Indirect estimate Network estimate Prediction interval	acebo 1	1.00			-0.59 -0.59	[-3.74; 2.56] [-3.74; 2.56] [-4.90; 3.72]
Ketamine:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	2	1.00	0%		-1.24 -1.24	[-2.99; 0.51] [-2.99; 0.51] [-4.44; 1.96]
Lidocaine:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	2	1.00	85%		-1.18 -1.18	[-2.91; 0.55] [-2.91; 0.55] [-4.37; 2.01]
Magnesium:Placeb Direct estimate Indirect estimate Network estimate Prediction interval	1	0.89			-0.40 -3.39 -0.74	[-2.74; 1.94] [-9.92; 3.13] [-2.94; 1.46] [-4.27; 2.79]

Figure 7a Forest plot for intervention efficiency compared to Placebo in NMA with detailed direct and

indirect comparisons

- 457 458
- 459
- 460
- 461

ī

Morphine:Placebo							
Direct estimate Indirect estimate	3	1.00	67%	+	-0.07 [-	1.63; 1.	.49]
Network estimate Prediction interval				-	-0.07 [- [-	1.63; 1. 3.15; 3.	.49] .01]
Naloxone:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	2	0.90	0%		0.12 [- 	1.92; 2. 2.68; 9. 1.48; 2. 2.88; 3.	.16] .29] .38] .78]
Nortriptyline:Placebo Direct estimate Indirect estimate	1	1.00			-0.65 [-	3.06; 1.	.76]
Network estimate Prediction interval					-0.65 [- [-	3.06; 1. 4.34; 3.	.76] .04]
Oxycodone:Placebo Direct estimate Indirect estimate Network estimate Prediction interval	1	0.65			-1.77 [- -1.70 [- -1.74 [- [-	4.12; 0. 4.90; 1. 3.64; 0. 5.05; 1.	.58] .51] .15] .56]
Phenytoin:Placebo Direct estimate Indirect estimate Network estimate	1	1.00			-0.80 [- -0.80 [-	3.93; 2. 3.93; 2.	.33] .33]
Placebo_GPN:Placeb Direct estimate	10 1	1.00			l- 0.70 [-	5.10, 5. 1.89; 3.	.29]
Network estimate Prediction interval					0.70 [- [-	1.89; 3. 3.14; 4.	.29] .54]
THC:Placebo Direct estimate Indirect estimate	1	1.00			-1.10 [-	3.77; 1.	.57]
Network estimate Prediction interval					-1.10 [- [-	3.77; 1. 5.00; 2.	.57] .80]
VPA:Placebo Direct estimate Indirect estimate	1	1.00			-0.60 [-	3.07; 1.	.87]
Network estimate Prediction interval					-0.60 [- [-	3.07; 1. 4.34; 3.	.87] .14]
				-0 0 J			

462

463 Figure 7b Forest plot for intervention efficiency compared to Placebo in NMA with detailed direct and 464 indirect comparisons

- 465
- 466

467 Subgroup Analysis468

A subgroup analyses was conducted for 24 studies within the meta-analysis to explore the sources of heterogeneity and unbiased estimation based on age, pain type, period and geographical location [Figure 8]. The sub-group analysis for pain type, time period and geographical location can be found in the supplementary file whilst average age is shown below.

474

476

475 Subgroup analysis for pain ccore difference based on different age groups

477 It showed that the heterogeneity among studies with participants who were older than 50 478 years old had changed with decreased I^2 ($I^2 = 48\%$ for "51-60", $I^2 = 68\%$ for "61-71"). A 479 common effects model was chosen for subgroup "51-60", which produced a higher 480 estimation of pain reduction with a mean difference of -1.46 (95% CI = [-1.74, -1.18]). Based 481 on the high heterogeneity ($I^2 > 50\%$), random effects models were built for other

subgroups. The group with participants younger than 40 years older obtained a significant drug efficiency (MD = -1.05, 95% CI = [-1.85, -0.24]). The pooled drug effects [Figure 8] in the 41-50 and 61-71 years of age groups were much lower than the overall treatment effect of NSAID drugs identified in the PMA. The 95% CI of 0 indicated statistically ineffective compared to the placebo. The random effects models showed the decrease of heterogeneity indicating that age may be a source of heterogeneity.

	E	Experimenta	d	C	ontrol				Weight
Study	Total	Mean SI	D Total	Mean	SD	Mean Difference	MD	95%-CI	(random)
aubanaun - cr 10						E			
Infl McCleane 1999 [Phenutein]	20	2 12 2 220	0 20	2 02	2 6600	10.00	0.00	1 2 00: 1 201	E 10/
[96] McClearle 1999 [Frienytoin]	20	3.13 3.220	0 20	7.40	3.5500		-0.00	[-2.90, 1.30]	0.1%
[100] Levendogiu et al. 2004 [Gabapentin]	20	5.20 1.200	0 20	2.40	4.2500	-	-4.20	[-4.01, -3.59]	9.4%
[45] Kimos et al. 2007 [Gabapentin]	20	3.50 3.000	0 20	2.43	4.3500		2.07	[0.36; 4.96]	4.0%
[70] Turekii et al. 2006 [VPA]	40	5.50 2.000	0 30	4.10	0.6000	_	-0.00	[-1.44, 0.24]	0.0%
[27] Bruchl et al. 2014 [Merchine]	50	2 42 2 800	0 50	2.04	2 7500		-1.37	[-2.12, -0.02]	9.0%
[37] Bruch et al. 2014 [Morphine]	50	2.42 2.090	0 50	1 00 1	2.7500		-0.02	[-1.73, 0.49]	0.070
[37] Bruchl et al. 2014 [Molphine]	50	2 04 2 910	0 50	3.04	2 7500		-0.90	[-3.31, 1.31]	9.0%
[37] Bruehl et al. 2014 [Naloxone]	50	5 20 6 100	0 50	4 90 1	2.7500		0.10	[-1.19, 0.99]	4 3%
[66] Shekeir & Mourea 2015 [Pupivaspine]	20	5.30 0.190	0 30	7 70	1 2600	-	2.20	[-1.95, 2.95]	4.5%
[00] Shokeli & Wousa 2015 [Dupivacalite]	50	1 60 1 010	0 30	5.40	1.2000		-2.50	[-2.75, -1.05]	9.0%
[33] AbdelHefeer et al. 2010 [Celecoxib]	20	4.00 1.910 5 10 0.670	0 40	5.40	0.0200	-	-0.00	[-1.30, -0.04]	9.0%
[3] AbdelHafeez et al. 2019 [Gabapentin]	30	3.12 0.070	0 30	5.50	1 1200		-0.70	[-1.19, -0.37]	9.0 %
[5] Abdelhaleez et al. 2019 [Gabapentin]	454	3.72 0.090	442	5.50	1.1300		4 50	[-2.25, -1.51]	9.770
Common effects model	454		443			1	-1.58	[-1.78; -1.38]	100.0%
Random effects model	00					-	-1.05	[-1.85; -0.24]	100.0%
Heterogeneity: $T = 91\%$, $T = 1.7716$, $p < 0.0$	11								
subgroup = 61-71									
[90] Mahowald et al. 2009 [IA- BoNT/A]	18	4.70 0.700	0 22	5.80	0.9000	+	-1.10	[-1.60; -0.60]	24.2%
[112] Clarke et al. 2009 [Gabapentin]	38	4.90 2.200	0 38	4.20	2.9000		0.70	[-0.46; 1.86]	19.6%
[30] Nenke et al. 2015 [Hydrocortisone]	7	5.00 2.530	0 19	5.59	2.2400		-0.59	[-2.72; 1.54]	12.6%
[43] Eker et al. 2016 [Lidocaine]	26	2.80 1.300	0 26	4.80	2.5000		-2.00	[-3.08; -0.92]	20.2%
[104] Hudson et al. 2021 [Nortriptyline]	102	3.60 2.320	0 103	4.25	2.4000	-	-0.65	[-1.30; -0.00]	23.4%
Common effect model	191		208			٠	-0.89	[-1.23; -0.54]	
Random effects model						•	-0.78	[-1.61; 0.06]	100.0%
Heterogeneity: $I^2 = 68\%$, $\tau^2 = 0.6261$, $\rho = 0.0$	01								
subgroup = 41-50									
[81] Cardenas et al. 2002 [Amitriptyline]	44	4.50 1.900	0 40	4.00	2.0000	+	0.50	[-0.34: 1.34]	15.5%
[48] Katz et al. 2005 [Bupropion]	44	3.25 1.930	0 44	3.42	1.8600	+	-0.17	[-0.96: 0.62]	15.7%
[88] Chu et al. 2012 [Morphine]	48	2.11 1.590	0 55	1.25	1.9200	+	0.86	[0.18: 1.54]	16.2%
[117] Kim et al. 2017 [Lidocaine]	39	2.40 0.700	0 39	2.90	0.7000	10	-0.50	[-0.81: -0.19]	17.5%
[117] Kim et al. 2017 [Magnesium]	38	2.50 0.600	0 39	2.90	0.7000		-0.40	[-0.69: -0.11]	17.6%
[71] Maarrawi et al. 2018 [Amitriptyline]	104	3.34 1.450	0 108	6.12	0.9200		-2.78	[-3.11: -2.45]	17.5%
Common effect model	317		325			+	-0.91	[-1.08: -0.75]	
Random effects model						-	-0.44	[-1.48: 0.59]	100.0%
Heterogeneity: $l^2 = 97\%$, $\tau^2 = 1.5880$, $p < 0.0$)1							•	
substaup = 54.60									
Subgroup = 51-60	20	2 40 2 200	0 00	4.00	2 1000		0.00	1 2 02: 0 221	44.40/
[56] Rashiq et al. 2003 [Pentanyi]	20	3.10 2.200	0 20	4.00	2.1000	_	-0.90	[-2.03; 0.23]	14.1%
[113] Malet al. 2007 [Oxycodone]	20	3.24 0.920	0 30	4.20	2.0000		-1.77	[-2.11, -1.43]	12 00/
[112] Clarke et al. 2009 [Gabapentin]	50	4.10 2.200	0 50	4.20	2.9000		-0.10	[-1.20, 1.00]	15.9%
[91] Lonus et al. 2010 [Retamine]	52	3.10 2.400	0 50	4.20	2.4000		-1.10	[-2.03; -0.17]	15.2%
[52] Han et al. 2016 [BTX-A]	20	6 39 3 750	0 20	7.45	0000	_	-0.80	[-1.95; 0.35]	12.0%
[77] do Vrice et al. 2016 [BTX-A]	20	0.30 2.750	0 20	2.50	2.0400		-1.30	[-2.00; 0.20]	12.0%
Common offect model	21	2.40 2.280	29	3.50	2.4200		-1.10	[-2.41, 0.21]	13.0%
Random offects model	231		243				-1.40	[-1.74, -1.18]	100.0%
Hateresseeity $I^2 = 40\%$ $r^2 = 0.4070$ $r = 0.0$	7						-1.13	[-1.03; -0.04]	100.0%
r_{101010} (generally, $r_{1} = 40\%$, $t_{1} = 0.107\%$, $p = 0.0$	66)).								
Heteroceneity: $l^2 = 92\% r^2 = 1.1367$ $n < 0.0$	11					-4 -2 0 2 4			

Heterogeneity: $l^2 = 92\%$, $\tau^2 = 1.1367$, $\rho < 0.01$ Test for subgroup differences (common effect): $\chi_3^2 = 32.38$, df = 3 ($\rho < 0.01$) Test for subgroup differences (random effects): $\chi_3^2 = 1.64$, df = 3 ($\rho = 0.65$)

488 489 490

Figure 8. Forest plot for the mean difference of pain scores between experimental group and control group across different mean age of participants.

491 Sensitivity Analysis

492

493 The sensitivity analysis was conducted [Figure 12] for the PMA where some studies influenced the pooled results compared to the overall estimation (-0.89). To test this theory, 494 495 study number 71 and 100 were omitted and the pooled results were much lower, -0.82 and -496 0.79, respectively. Studies with Amitriptyline and Gabapentin produced unstable treatment 497 results, and the absence of these showed an overestimation (study 81, 45) or underestimates (study 71, 100). Collectively, the high heterogeneity ($I^2 = 92\%$, p-value < 498 0.01) was stable and a robust treatment effect with negative mean differences and a 499 500 significant 95% CI remained. Therefore, the pooled treatment effects identified was credible.

Study	Mean Difference	MD	95%-CI	P-value	Tau2	Tau	12
Omitting [71] Maarrawi et al. 2018 [Amitriptyline]	*	-0.82	[-1.23; -0.41]	< 0.01	1.0254	1.0126	89%
Omitting [81] Cardenas et al. 2002 [Amitriptyline]		-0.94	[-1.36; -0.52]	< 0.01	1.1032	1.0503	92%
Omitting [52] Han et al. 2016 [Botulinum]	+	-0.89	[-1.32; -0.46]	< 0.01	1.1794	1.0860	92%
Omitting [52*] Han et al. 2016 [Botulinum]		-0.88	[-1.31; -0.45]	< 0.01	1.1720	1.0826	92%
Omitting [90] Mahowald et al. 2009 [Botulinum]	÷.	-0.88	[-1.32; -0.44]	< 0.01	1.1890	1.0904	92%
Omitting [66] Shokeir & Mousa 2015 [Bupivacaine]	+	-0.84	[-1.26; -0.41]	< 0.01	1.1053	1.0513	92%
Omitting [48] Katz et al. 2005 [Bupropion]	+	-0.92	[-1.35; -0.48]	< 0.01	1.1614	1.0777	92%
Omitting [93] Kahlenberg et al. 2017 [Celecoxib]	÷	-0.89	[-1.33; -0.46]	< 0.01	1.1855	1.0888	92%
Omitting [56] Rashiq et al. 2003 [Fentanyl]	÷	-0.89	[-1.32; -0.45]	< 0.01	1.1805	1.0865	92%
Omitting [3] AbdelHafeez et al. 2019 [Gabapentin]	*	-0.89	[-1.33; -0.46]	< 0.01	1.1894	1.0906	92%
Omitting [3*] AbdelHafeez et al. 2019 [Gabapentin]		-0.85	[-1.29; -0.42]	< 0.01	1.1585	1.0763	92%
Omitting [45] Kimos et al. 2007 [Gabapentin]	-	-0.96	[-1.37; -0.55]	< 0.01	1.0330	1.0163	92%
Omitting [100] Levendoglu et al. 2004 [Gabapentin]	*	-0.79	[-1.15; -0.43]	< 0.01	0.7235	0.8506	90%
Omitting [112] Clarke et al. 2009 [GPN_Placebo]	+	-0.91	[-1.34; -0.48]	< 0.01	1.1573	1.0758	92%
Omitting [30] Nenke et al. 2015 [Hydrocortisone]	÷	-0.89	[-1.32; -0.47]	< 0.01	1.1625	1.0782	92%
Omitting [87] Schwartzman et al. 2009 [Ketamine]	÷	-0.87	[-1.30; -0.44]	< 0.01	1.1798	1.0862	92%
Omitting [91] Loftus et al. 2010 [Ketamine]	÷	-0.88	[-1.31; -0.45]	< 0.01	1.1832	1.0877	92%
Omitting [43] Eker et al. 2016 [Lidocaine]		-0.85	[-1.28; -0.42]	< 0.01	1.1477	1.0713	92%
Omitting [117] Kim et al. 2017 [Lidocaine]		-0.90	[-1.34; -0.47]	< 0.01	1.1815	1.0870	92%
Omitting [117] Kim et al. 2017 [Magnesium]		-0.91	[-1.34; -0.47]	< 0.01	1.1766	1.0847	91%
Omitting [37] Bruehl et al. 2014 [Morphine]		-0.90	[-1.33; -0.46]	< 0.01	1.1771	1.0850	92%
Omitting [37*] Bruehl et al. 2014 [Morphine]	÷	-0.89	[-1.32; -0.46]	< 0.01	1.1611	1.0775	92%
Omitting [88] Chu et al. 2012 [Morphine]		-0.96	[-1.38; -0.55]	< 0.01	1.0459	1.0227	91%
Omitting [37] Bruehl et al. 2014 [Naloxone]	÷	-0.91	[-1.34; -0.48]	< 0.01	1.1572	1.0758	92%
Omitting [37*] Bruehl et al. 2014 [Naloxone]		-0.91	[-1.34; -0.49]	< 0.01	1.1399	1.0677	92%
Omitting [104] Hudson et al. 2021 [Nortriptyline]		-0.90	[-1.33; -0.46]	< 0.01	1.1841	1.0882	92%
Omitting [113] Ma et al. 2007 [Oxycodone]		-0.85	[-1.28; -0.42]	< 0.01	1.1588	1.0765	92%
Omitting [96] McCleane 1999 [Phenytoin]		-0.89	[-1.32; -0.46]	< 0.01	1.1645	1.0791	92%
Omitting [112] Clarke et al. 2009 [Placebo_GPN]		-0.94	[-1.36; -0.52]	< 0.01	1.0967	1.0473	92%
Omitting [77] de Vries et al. 2016 [THC]	÷	-0.88	[-1.31; -0.45]	< 0.01	1.1770	1.0849	92%
Omitting [70] Yurekli et al. 2008 [VPA]	*	-0.90	[-1.33; -0.46]	< 0.01	1.1803	1.0864	92%
Random effects model	⊢ ,∔,-,	-0.89	[-1.31; -0.47]	< 0.01	1.1367	1.0662	92%
	-4 -2 0 2 4						

501 502	
503	
504	
505	
506	
507	

Figure 12 Forest plot for Sensitivity Analysis with studies in MA

508 Publication bias

509
510 The funnel plots [Figure 13] within the PMA indicated symmetry. Although several studies
511 were not within the remit of the funnel, the Egger's test showed a p value (0.22) larger than
512 0.05 which indicated the lack of small-study effects.



513 514

515 516

517 518

Figure 13 Funnel plot for studies used in PMA

Table 5 Egger test results for studies used in PMA

Test result:	t = 1.24, df = 29, p-value = 0.2247							
	bias	se.bias	intercept	se.intercept				
Sample estimates:	1.49	1.2	-1.593	0.3737				

- 519
- 520
- 521 522

523

524 Discussion

525

526 We identified opiods and non-opiods were the two primary classes of pharmacological 527 interventions in chronic pain management. The long-term use of opioids in the management 528 of chronic non-malignant pain has come under scrutiny over the last few years and is now 529 recommended that it should be offered only if benefits of initiating treatment would 530 significantly outweigh the potential risks, and possibly as an adjunct to the primary 531 intervention^[30]. Our study has shown that judicious use of non-opioid medications along with 532 other treatment modalities could provide better outcomes in managing chronic pain thereby 533 removing long-term side-effects observed during opioid therapy. Opioids are widely used in the management of cancer pain and also non-cancer associated pain ^[25,26] However, recent 534 535 evidence also indicates that opioids provide limited advantage in managing chronic noncancer pain and have similar efficacy to non-opioids.^[29] The awareness of an opioid crisis 536

globally has prompted clinicians to exercise caution in their prescription habits, but the WHO
 supports the use of opioids including Fentanyl and Methadone as an essential class of
 medication for the management of cancer pain^[27,28].

540

541 The meta-analysis of baseline pain scores lacked statistical significance between 542 experimental and control groups. The significant reduction in chronic pain scores of patients 543 taking NSAID versus non-steroidal opioid drugs compared to patients given placebo under a 544 random effects model. The presence of a significant drug efficiency with BTX-A and 545 Ketamine in interesting although the pooled results of other drugs and interventions had 546 statistically insignificant results with a 95% CI of 0. The pooled evidence indicated Ketamine 547 showed the highest pain reduction (1.26) followed by BTX-A (0.98). Studies testing on other 548 drugs including Amitriptyline, Gabapentin, Morphine and Lidocaine had a high heterogeneity 549 and insignificant drug efficiency. Overall, evidence from the PMA showed a strong efficacy 550 within the NSAIDs group with managing pain which were remarkably narrowed when 551 exclusive trials with low risk of bias were included^[11].

552

553 Many cancer patients are increasingly being cured or achieve long term remission, and 554 prolonged use of opioids could result in aberrant behaviour and dependence, thus limiting 555 opioid use to patients with a terminal illness or as part of end-of-life care. The CDC 556 recommends the use of non-pharmacological therapies and non-opioid pharmacotherapy as 557 the primary intervention in patients with chronic pain, and opioids should be offered only if 558 benefits of initiating treatment significantly outweigh the potential risks and if possible, these should be used as an adjunct to the primary intervention.^{[30].} In this study, a pairwise meta-559 560 analysis and NMA consolidating the evidence of 46 studies was carried out, with the former 561 Morphine has traditionally been used for the comparing several different opioids. management of moderate to severe chronic pain.^[33] Despite morphine being a potent 562 563 analgesic [MD = 0.01 (95% CI=[-1.18, 1.21], newer opioids are now being employed owing to 564 their superior safety profile. Oxycodone and Fentanyl appear to be popular due to better 565 availability and vast clinical experience including the well accepted effectiveness 566 demonstrated, as per patient and clinically reported outcomes. Our results are aligned to 567 these trends where the effectiveness is shown to include a MD 1.77 (95% CI=[-2.11,-1.43]) for Oxycodone and a MD of -0.90 (95% CI=[-2.03,0.23])] for Fentanyl .^[32] However, 568 569 untoward gastrointestinal effects (constipation, nausea, and vomiting) still remain a major concern with opioid use and are often responsible for discontinuation of treatment.^[34,35] 570 571 Recent evidence favours the use of a combination of oxycodone and naloxone in patients 572 with chronic pain (after ensuring that there is no cause for porto-systemic anastomosis), to 573 offer an improved bowel function without any effective change in analgesia.^[36]. The concerns 574 of developing tolerance, opioid-induced hyperalgesia, aberrant behaviour and dependence 575 with opioids is a pragmatic reason to develop effective alternative treatment modalities 576 especially for vulnerable individuals. In pairwise comparison, we observed Ketamine to be 577 superior to other pharmacological interventions with a mean difference MD -1.26 (95% CI=[-578 1.85,-0.68]).

579

There are several guidelines recommending the use of Pregabalin, Gabapentin, Duloxetine, and Amitriptyline as first line drugs in the management of neuropathic pain ^[37]. However, the use of gabapentinoids is being challenged as it lacks favourable robust evidence for efficacy against pain syndromes other than fibromyalgia, post herpetic neuralgia and diabetic neuropathy, and many clinicians have also highlighted the potential for misuse and

developing dependence^[38,39,40]. The use of BTX-A, Ketamine, Ningmitai and THC for the 585 management of various chronic pain conditions is popular and well established^[12,13,14,15] and 586 587 our study shows the effective use of these as analgesics when compared to placebo. There 588 is evidence to support the efficacy of BTX-A for the management of neuropathic pain 589 although the sample sizes used in the studies were small and therefore the real-world applicability remains limited^[16]. BTX-A is also used in management of myofascial pains^[17,18] 590 591 although further evidence on the efficacy and tolerability within all populations, especially 592 those with existing co-morbidities needs to be evaluated. Ketamine was found to be beneficial in managing some neuropathic pains^[19] and as an infusion the rates of serious 593 adverse effects were found to be similar to placebo.^[20] 3,24] Further studies are required to 594 595 gather evidence to better understand its psychedelic effects and its role in the management 596 of PTSD, anxiety and depression . A renewed use of magnesium in managing chronic pain has been demonstrated in some literature.^[50] Our results indicate similar evidence in the use 597 of magnesium, but will require further research to determine the efficacy, safety and 598 599 effectiveness in managing short, medium and long-term pain.

600

The NMA provided more reliable results with direct and indirect comparisons between different drugs under different study designs. However, only a small number of multi-arm trials were eligible and the distribution of trials studying different drugs was uneven. It resulted in the lack of direct evidence of certain drugs and their relative efficacy in the network was unstable due to excessive reliance on indirect comparisons. Therefore, well designed and robust clinical trials should be conducted to verify the efficacy of pharmaceutical interventions used in chronic pain management.

608

609 Conclusion

610 To the best of our knowledge, this is the first pairwise MA and NMA reporting the synthesis 611 of the prevalence of the efficacy of pharmacological treatments used in the management of 612 chronic pain with a large sample size of 17,708 participants. Management of long-term 613 chronic pain needs to be prioritised for several reasons including humanitarian, the strain on 614 the healthcare systems and the impact on the economy due to loss of productivity. The use 615 of pharmaceutical agents in the long-term management of chronic pain has been debated for 616 several decades, yet there has not been a consensus on this matter. This study supports 617 the importance of generating better evidence by way of robust clinical trials, the need for 618 drafting clinical guidelines that is pragmatic, practical as well as clinically significant and the 619 use of better data-connectivity methods to improve clinical practice in the real-world.

- 620 621 622 623
- 624
- 625
- 626
- 627
- 628
- 629
- 630 631 <u>Appendix</u>

632

Table 6 Intervetions used in studies

Study_Number	Author	Intervetion Abbreviation	Intervetion Details
1	Weizman et al.	THC	Cannabis
2	Krebs et al.	Opioid	opioid and nonopioid medication therapy
3	AbdelHafeez et al.	Gabapentin	Gabapentin 2700 mg daily
4	Bushey et al.	Opioid	analgesic
5	Bruehl et al.	Morphine + Naloxone	Morphine and Naloxone
6	Worley et al.	Buprenorphine/Naloxone	Buprenorphine/naloxone
7	Dindo et al.	ACT	Acceptance and Commitment Therapy
8	Hruschak et al.	IPGT	psychoeducation, motivational interviewing, cognitive behavioral therapy, mindfulness, and peer suppor
9	Azevedo et al.	Opioid	Opioid
10	Gudin et al.	NKTR-181	NKTR-181 administered at doses of 100– 600 □ mg twice daily
11	Stahl et al.	Venlafaxine	lower-dose venlafaxine ($\leq 150 \square mg/d$)
12	Schliessbach et al.	Imipramine	imipramine 75
13	Mohamed et al.	Morphine	topical morphine (in 1 of 3 doses: 5, 10, or 15 mg)
14	Schliessbach et al.	Oxycodone+Imipramine+Clobazam	Oxycodone 15 mg, imipramine 75 mg, clobazam 20 mg
15	Hermans et al.	Naloxone	0 mg morphine or 0.2 mg/mL Naloxone) and placebo (2 mL Aqua) group.
16	Todorov et al.	Gabapentin+Tiagabine	Gabapentin and Tiagabine
17	Sadatsune et al.	Gabapentin	Gabapentin Group received 600 mg of gabapentin preoperatively, one hour prior to surgery, and Control Group received placebo.
18	Edwards et al.	Opioid	oral opioid therapy,
19	Katz et al.	Naproxen+Tanezumab	intravenous tanezumab 200 μ g/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41).
20	Hayek et al.	Opioid+Bupivacaine	opioid with bupivacaine
21	Schliessbach et al.	Clobazam	received a single oral dose of clobazam 20 mg or active placebo tolterodine 1 mg
22	Bruehl et al.	Opioid	Opioid
23	Kim et al.	Nefopam	infused with the same volume of saline or nefopam (0.2 mg/kg bolus, 120 µg/kg/h continuous infusion) during surgery
24	Eisenach et al.	Ketorolac	drug administration
25	Rauck et al.	Adenosine/Clonidine	intrathecal clonidine, 100 µg, or adenosine, 2 mg
26	Buchheit et al.	Valproate	oral valproic acid
27	Papadokostakis et al.	Calcitonin	200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily
28	Gould et al.	Desipramine	desipramine titrated to reach a serum concentration level of 15 to 65 ng/mL;

29	Schnitzer et al.	D-cycloserine	D-cycloserine
30	Nenke et al.	Hydrocortisone	10 mg/m2/day of oral hydrocortisone in three divided doses o
31	Sopata et al.	Opioid	opioids
32	Kendall et al.	Lidocaine	1.5 mg/kg bolus of intravenous lidocaine followed by a 2 mg/kg/hour infusion
33	Hongo et al.	Risedronate+Elcatonin	risedronate plus elcatonin
34	Amr & Yousef	Venlafaxine+Gabapentin	Venlafaxine 37.5 mg/d, gabapentin 300 mg/d
35	Pedersen et al.	Codeine+Paracetamol	30 mg codeine and 400 or 500 mg of paracetamol
36	Choi et al.	Lidocaine	The patients received 2 mg/kg of lidocaine followed by continuous infusions of 3 mg/kg/h of lidocaine
37	Bruehl et al.	Morphine+Naloxone	naloxone (8 mg), morphine (0.08 mg/kg)
38	Chrubasik et al.	Capsicum	cream containing capsaicin 0.05%
39	Schliessbach et al.	Oxycodone	oxycodone 15mg
40	Bruehl & Chung	Naloxone	8 mg dose of naloxone
41	Bruehl et al.	Naloxone+Morphine	naloxone, morphine
42	Burns et al.	Naloxone+Morphine	naloxone and morphine
43	Eker et al.	Lidocaine	Group I (n = 26) received 7 mL 0.5% lidocaine
44	Kim et al.	Opioid	opioid therapy
45	Kimos et al.	Gabapentin	gabapentin
46	Narang et al.	Opioid	Opioids
47	Peyton et al.	Ketamine	Ketamine,
48	Katz et al.	Bupropion	bupropion
49	Hashmi et al.	Lidocaine	Lidocaine
50	Shimoyama et al.	Fentanyl	fentanyl
51	Wreje & Brorsson	Sterile water	sterile water
52	Han et al.	BTX-A	botulinum toxin type A
53	Rauck et al.	Hydrocodone	hydrocodone 20-100 ang every 12 hours)
54	Kim et al.	Pregabalin	pregabalin
55	Lee et al.	BTX-A	Botulinum Toxin Injection
56	Rashiq et al.	Fentanyl	Opioid
57	Kang et al.	Ketamine	0.12 mg/kg/h of ketamine
58	Lipton et al.	Erenumab	erenumab 70 and 140 ang
59	Williamson et al.	Duloxetine	duloxetine
60	Guo et al.	Celecoxib Eperisone	Celecoxib Eperisone
61	Damjanov et al.	ACS	Autologous conditioned serum (ACS; marketed as Orthokine®)
62	Abd-Elshafy et al.	Bupivacaine	Drug: Dexmedetomidine isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) Drug: Bupivacaine isobaric bupivacaine 0.5% (0.3ml/kg)

63	Levesque et al.	BTX+Ropivacaïne	Drug: botulinum toxin A + ropivacaïne Drug: Ropivacaïne
64	Maher et al.	Ketamine	Ketamine
65	Barry et al.	Methadone	Methadone
66	Shokeir & Mousa	Bupivacaine	bupivacaine
67	Scudds et al.	Lidocaine	lidocaine
68	Gimbel et al.	Buccal buprenorphine	buccal buprenorphine
69	Matsuoka et al.	Duloxetine	duloxetine 20 mg
70	Yurekli et al.	Sodium valproate	sodium valproate
71	Maarrawi et al.	Amitriptyline	amitriptyline
72	Li et al.	Ropivacaine+Dexamethasone	single 20-mL injection of 0.50% ropivacaine plus 10 mg dexamethasone
73	Almog et al.	THC	THC: 0.5mg, 1mg
74	Wylde et al.	Bupivacaine	anaesthetic with 3 mL of 0.5% plain bupivacaine
75	Matsukawa et al.	Cernitin+Tadalafil	Tadalafil
76	Haddad et al.	Apomorphine	Apomorphine
77	de Vries et al.	THC	Tetrahydrocannabinol
78	Urquhart et al.	Amitriptyline	amitriptyline; 25mg per day
79	Lichtman et al.	Nabiximols	nabiximols
80	Schiphorst et al.	Acetaminophen/Tramadol	acetaminophen/tramadol 325 mg/37.5 mg
81	Cardenas et al.	Amitriptyline	amitriptyline
82	Arnold et al.	Milnacipran	chronic pain
83	Wasan et al.	Morphine	morphine
84	Baron et al.	Tapentadol/Pregabalin	tapentadol PR 300 mg/day+pregabalin
85	Portenoy et al.	Fentanyl	Fentanyl
86	Likar et al.	Morphine	morphine hydrochloride
87	Schwartzman et	Ketamine	ketamine
88	Chu et al.	Morphine	Morphine
89	Sandrini et al.	BoNTA	onabotulinum toxin A
90	Mahowald et al.	BoNTA	Botulinum Toxin Type A
91	Loftus et al.	Ketamine	ketamine infusions
92	Lehmann et al.	Fentanyl	Transdermal fentanyl
93	Kahlenberg et al.	Celecoxib	celecoxib
94	Silberstein et al.	Topiramate	topiramate
95	Burgher et al.	Lidocaine	lidocaine and either clonidine (200 or 400mcg) or triamcinolone
96	McCleane	Phenytoin	phenytoin (Parke Davis)
97	Naliboff et al.	Opioid	Opioids
98	Booth et al.	Morphine	300 mcg spinal morphine and 1 gram acetaminophen

99	Lee et al.	Rowatinex/Ibuprofen	rowatinex 200 mg /ibuprofen 600 mg
100	Levendoglu et al.	Gabapentin	Gabapentin
101	Yousef & Alzeftawy	Opioid	oral perixicam
102	Yelland et al.	Gabapentin	gabapentin
103	Yucel et al.	Venlafaxine	venlafaxine
104	Hudson et al.	Nortriptyline	nortriptyline
105	Rauck et al.	Ziconotide	ziconotide
106	Sandner- Kiesling et al.	Naloxone+Oxycodone	oxycodone PR/naloxone PR
107	Wang et al.	Diosmin	Diosmin
108	Hawley et al.	Lidocaine	Lidocaine
109	Mathieson et al.	Pregabalin	pregabalin at a dose of 150 mg
110	Wetzel et al.	Nonopioid analgesic drugs	oral nonopioid analgesic drug
111	Khan et al.	Lidocaine+Pregabalin	pregabalin
112	Clarke et al.	Gabapentin	Gabapentin
113	Ma et al.	Oxycodone	oxycodone
114	J. H. Lee & C. S. Lee	TA-ER	tramadol hydrochloride 75- mg/acetaminophen 650-mg
115	Imamura et al.	Lidocaine	paraspinous lidocaine injection
116	Baron et al.	Tapentadol	Tapentadol
117	Kim et al.	Lidocaine+Magnesium	lidocaine (L), magnesium (M
118	Iwamura et al.	Eviprostat	Eviprostat
119	Zhang et al.	Ningmitai	Ningmitai Capsule

633

634 635

636 <u>References</u>

637

640

641 642

643

644

645 646

647 648

649

650 651

- 638 639
- Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:1001–1006. DOI: http://dx.doi.org/10.15585/mmwr.mm6736a2external icon
- Salanti G. Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012 Jun;3(2):80-97. doi: 10.1002/jrsm.1037. Epub 2012 Jun 11. PMID: 26062083.
 - Brown, C.A., Lilford, R.J. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 6, 54 (2006). <u>https://doi.org/10.1186/1471-2288-6-54</u>
- 4. Lumley, T. "Network Meta-analysis for Indirect Treatment Comparisons." Statistics in Medicine 21 (2002): null. <u>https://doi.org/10.1002/SIM.1201</u>.

654		
655	5.	Li, T., Puhan, M.A., Vedula, S.S. et al. Network meta-analysis-highly
656		attractive but more methodological research is needed. BMC Med 9, 79
657		(2011). https://doi.org/10.1186/1741-7015-9-79
658		
659	6.	Caldwell, D., A. Ades, and J. Higgins, "Simultaneous Comparison of
660	•	Multiple Treatments: Combining Direct and Indirect Evidence " BM.I: British
661		Medical lournal 331 (2005): 897-
662		900 https://doi.org/10.1136/bmi.331.7521.897
662		500. https://doi.org/10.1150/binj.551.7521.657.
664	7	Janson ID Elouropeo D. Doving P. Itzlar D. Parrett A. Howking N. Leo K.
	1.	Jaliseli JF, Fleulence R, Devine D, Ilziel R, Dallell A, Hawkins N, Lee R,
005		boersma C, Annemans L, Cappenen JC. Interpreting indirect treatment
666		compansons and network meta-analysis for nealth-care decision making:
667		report of the ISPOR task force on indirect treatment comparisons good
668		research practices: part 1. Value Health. 2011;14(4):417–28.
669	_	
670	8.	Effhimiou O, Debray TP, van Valkenhoef G, Trelle S, Panayidou K, Moons
671		KG, Reitsma JB, Shang A, Salanti G. GetReal in network meta-analysis: a
672		review of the methodology. Res Synth Methods. 2016;7(3):236–63.
673		
674		
675	9.	Dallenbach KM. Pain: History and present status. Am J Psychol 1939; 52:
676		331.
677		
678	10	Turk DC and Monarch ES. Biopsychosocial perspective on chronic pain. In:
679		Turk DC. Gatchel RJ. eds. Psychological Approaches to Pain
680		Management: A Practitioner's Handbook 2nd ed Guilford New York
681		2002
682		2002
683	11	Brown C.A. Lilford R.I. The stepped wedge trial design: a systematic
684		review BMC Med Res Methodol 6 54 (2006) https://doi.org/10.1186/1471-
604 605		2288 6 54
685		2200-0-34
000	10	Comphell I (1006 November 11) Presidential Address Speech rives at
007	12	the American Dain Society Weekington, DC
000		the American Pain Society, Washington, DC
689	40	Zierman Z. Erssen K. Orel Drehen study H. Zeissense A. A. elskal study of a sig
690	13	Zimmer Z, Fraser K, Groi-Prokopczyk H, Zajacova A. A global study of pain
691		prevalence across 52 countries: examining the role of country-level
692		contextual factors: Examining the role of country-level contextual factors.
693		Pain 2022; 163: 1740–50.
694		
695	14	Relieving pain in America: A blueprint for transforming prevention, care,
696		education, and research. Washington, D.C.: National Academies Press,
697		2011.
698		
699	15	Caldwell, D., A. Ades, and J. Higgins. "Simultaneous Comparison of
700		Multiple Treatments: Combining Direct and Indirect Evidence." BMJ: British
701		Medical Journal 331 (2005): 897–
702		900. https://doi.org/10.1136/bmj.331.7521.897.
703		,

- 704 16.U.S. Department of Health and Human Services (2019, May). Pain 705 Management Best Practices Inter-Agency Task Force Report: Updates, 706 Gaps, Inconsistencies, and Recommendations. Retrieved from U.S. 707 Department of Health and Human Services website: 708 https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html. .
- 710 17.Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2010): A basic
 711 introduction to fixed-effect and random-effects models for meta-analysis.
 712 Research Synthesis Methods, 1, 97–111
- 18. Rothstein, H.R., Sutton, A.J., Borenstein, M.: Publication Bias in Meta
 Analysis: Prevention, Assessment and Adjustments. Wiley, Chichester
 (2005)
- 19. Béliveau A, Boyne DJ, Slater J, Brenner D, Arora P. BUGSnet: an R
 package to facilitate the conduct and reporting of Bayesian network Metaanalyses. BMC Med Res Methodol. 2019 Oct 22;19(1):196. doi:
 10.1186/s12874-019-0829-2. PMID: 31640567; PMCID: PMC6805536.
- 20. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K,
 Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment
 comparisons and network meta-analysis for health-care decision making:
 report of the ISPOR task force on indirect treatment comparisons good
 research practices: part 1. Value Health. 2011;14(4):417–28.
- 729 21. Opioid overdose. Who.int□: www.who.int/news-room/fact 730 sheets/detail/opioid-overdose. .
- 22. Ho KY, Cardosa MS, Chaiamnuay S, et al. Practice advisory on the
 appropriate use of NSAIDs in primary care. J Pain Res 2020; 13: 1925–39.
- 737 23. Chung JW, Zeng Y, Wong TK. Drug therapy for the treatment of chronic
 738 nonspecific low back pain: systematic review and meta-analysis. Pain
 739 Physician 2013; 16: E685-704.
- 24. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering
 Committee. Assessment of upper gastrointestinal safety of etoricoxib and
 diclofenac in patients with osteoarthritis and rheumatoid arthritis in the
 Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL)
 programme: a randomised comparison. Lancet 2007; 369: 465–73.
- 747 25. Griffin MR. High-dose non-steroidal anti-inflammatories: painful choices.
 748 Lancet 2013; 382: 746–8.
- 750 26. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non 751 steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:
 752 c7086.
- 753

709

713

717

722

728

731 732 733

736

740

746

749

754 755 756 757	27. da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non- steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ 2021; 375: n2321.
758 759 760 761	28. Overview Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain Guidance NICE. https://www.nice.org.uk/guidance/ng193 (accessed Dec 9, 2022).
762 763 764	29. Eccleston C, Aldington D, Moore A, de C Williams AC. Pragmatic but flawed: the NICE guideline on chronic pain. Lancet 2021; 397: 2029–31.
765 766 767	30. Wood H. Anti-inflammatory drugs could cause chronic pain. Nat Rev Neurol 2022; 18: 382.
768 769 770 771	31. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non- surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; 27: 1578–89.
772 773 774 775	32. Enthoven WTM, Roelofs PDDM, Deyo RA, van Tulder MW, Koes BW. Non- steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev 2016; 2: CD012087.
776 777 778 779 780	33. Hary V, Schitter S, Martinez V. Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: A systematic review of randomized controlled trials and meta-analysis. Eur J Pain 2022; 26: 980– 90.
781 782 783 784	34. Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesth Analg 2019; 129: 241–54.
785 786 787 788	35. Jin C, Chen Z, Zhang J. Meta-analysis of the efficacy of Ningmitai capsule on the treatment of chronic prostatitis in China. Medicine (Baltimore) 2018; 97: e11840.
788 789 790 791 792	36. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis: A systematic review and meta-analysis. JAMA 2015; 313: 2456–73.
793 794 795 796 797	37. Wei J, Zhu X, Yang G, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav 2019; 9: e01409.
798 799 800	38. Khalifeh M, Mehta K, Varguise N, Suarez-Durall P, Enciso R. Botulinum toxin type A for the treatment of head and neck chronic myofascial pain syndrome. J Am Dent Assoc 2016; 147: 959-973.e1.
802 803	39. Meister MR, Brubaker A, Sutcliffe S, Lowder JL. Effectiveness of botulinum toxin for treatment of symptomatic pelvic floor myofascial pain in women: A

804 systematic review and meta-analysis: A systematic review and meta-805 analysis. Female Pelvic Med Reconstr Surg 2021; 27: e152-60. 806 807 40. Guimarães Pereira JE, Ferreira Gomes Pereira L, Mercante Linhares R, Darcy Alves Bersot C, Aslanidis T, Ashmawi HA. Efficacy and safety of 808 809 ketamine in the treatment of neuropathic pain: A systematic review and 810 meta-analysis of randomized controlled trials. J Pain Res 2022; 15: 1011-811 37. 812 813 41. Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the 814 use of intravenous ketamine infusions for chronic pain from the American 815 society of regional anesthesia and pain medicine, the American academy 816 of pain medicine, and the American society of anesthesiologists. Reg 817 Anesth Pain Med 2018: : 1. 818 42. Zhang K, Liu Y, Yang W, et al. Efficacy and safety of Ningmitai capsule in 819 820 patients with chronic prostatitis/chronic pelvic pain syndrome: A multicenter, randomized, double-blind, placebo-controlled trial. Urology 821 822 2021; 153: 264-9. 823 824 43. Jing Z, Living G, Zhenging W, et al. Efficacy and safety of Ningmitai 825 capsules in patients with chronic epididymitis: A prospective, parallel 826 randomized controlled clinical trial. Evid Based Complement Alternat Med 827 2021; 2021: 9752592. 828 829 44. Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people 830 with chronic non-cancer pain prescribed opioids: findings from a 4-year 831 prospective cohort study. Lancet Public Health 2018; 3: e341–50. 832 45. Boland EG, Bennett MI, Allgar V, Boland JW. Cannabinoids for adult 833 834 cancer-related pain: systematic review and meta-analysis. BMJ Support 835 Palliat Care 2020; 10: 14–24. 836 46. Pergolizzi JV Jr, Magnusson P, Christo PJ, et al. Opioid therapy in cancer 837 838 patients and survivors at risk of addiction, misuse or complex dependency. 839 Front Pain Res (Lausanne) 2021; 2: 691720. 840 841 47. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid 842 therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009; 843 18: 1166–75. 844 845 48. The Lancet Public Health. Opioid overdose crisis: time for a radical rethink. Lancet Public Health 2022; 7: e195. 846 847 848 49. World Health Organization Model List of Essential Medicines – 22nd List, 849 2021. Geneva: World Health Organization; 2021 850 (WHO/MHP/HPS/EML/2021.02) 851

852 853 854 855	50. Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: A systematic review and meta-analysis: A systematic review and meta-analysis. JAMA 2018; 320: 2448–60.
856 857 858 859	51. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for Prescribing Opioids for pain - United States, 2022. MMWR Recomm Rep 2022; 71: 1–95.
860 861 862	52. Meng Z, Yu J, Acuff M, et al. Tolerability of opioid analgesia for chronic pain: A network meta-analysis. Sci Rep 2017; 7: 1995.
863 864 865 866	53. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68.
867 868 869	54. World Health Organization. Cancer pain relief, second edition, with a guide to opioid availability. Geneva: World Health Organization; 1996
870 871 872 873 874	55. Noori A, Sadeghirad B, Wang L, et al. Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials. Br J Anaesth 2022; 129: 394–406.
875 876 877 878	56. Gehling M, Hermann B, Tryba M. Meta-analysis of dropout rates in randomized controlled clinical trials: opioid analgesia for osteoarthritis pain: Opioid analgesia for osteoarthritis pain. Schmerz 2011; 25: 296–305.
879 880 881 882 883 884	57. Huang L, Zhou J-G, Zhang Y, et al. Opioid-induced constipation relief from fixed-ratio combination prolonged-release oxycodone/naloxone compared with oxycodone and morphine for chronic nonmalignant pain: A systematic review and meta-analysis of randomized controlled trials. J Pain Symptom Manage 2017; 54: 737-748.e3.
885 886 887 888	58. Schlereth T. Guideline "diagnosis and non interventional therapy of neuropathic pain" of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract 2020; 2: 16.
889 890 891	59. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6: CD007938.
892 893 894 895	60. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta- analysis of randomized controlled trials. PLoS Med 2017; 14: e1002369.
896 897 898	61. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs 2017; 77: 403–26.
899 900	62. Alberti FF, Becker MW, Blatt CR, Ziegelmann PK, da Silva Dal Pizzol T, Pilger D. Comparative efficacy of amitriptyline, duloxetine and pregabalin

901 for treating fibromyalgia in adults: an overview with network meta-analysis. 902 Clin Rheumatol 2022; 41: 1965–78. 903 904 63. Urguhart DM, Wluka AE, van Tulder M, et al. Efficacy of low-dose 905 amitriptyline for chronic low back pain: A randomized clinical trial: A 906 randomized clinical trial. JAMA Intern Med 2018; 178: 1474-81. 907 908 64. Sankar V, Oommen AE, Thomas A, Nair JV, James JS. Efficacy, safety 909 and cost effectiveness of amitriptyline and pregabalin in patients with 910 peripheral neuropathy. Indian J Pharm Sci 2017; 79. diabetic 911 DOI:10.4172/pharmaceutical-sciences.1000274. 912 913 65. Levene JL, Weinstein EJ, Cohen MS, et al. Local anesthetics and regional 914 anesthesia versus conventional analgesia for preventing persistent 915 postoperative pain in adults and children: A Cochrane systematic review 916 and meta-analysis update. J Clin Anesth 2019; 55: 116–27. 917 918 66.Donado C, Lobo K, Velarde-Álvarez MF, et al. Continuous regional 919 anesthesia and inpatient rehabilitation for pediatric complex regional pain 920 syndrome. Reg Anesth Pain Med 2017; 42: 527-34. 921 922 67. Meng H, Fei Q, Wang B, et al. Epidural injections with or without steroids in 923 managing chronic low back pain secondary to lumbar spinal stenosis: a 924 meta-analysis of 13 randomized controlled trials. Drug Des Devel Ther 925 2015; 9: 4657–67. 926 927 68. Egli S, Pfister M, Ludin SM, Puente de la Vega K, Busato A, Fischer L. 928 Long-term results of therapeutic local anesthesia (neural therapy) in 280 929 referred refractory chronic pain patients. BMC Complement Altern Med 930 2015; 15: 200. 931 932 69. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic 933 administration of local anesthetic agents to relieve neuropathic pain. 934 Cochrane Database Syst Rev 2005; : CD003345. 935 936 70. Abd-Elshafy SK, Abdallal F, Kamel EZ, et al. Paravertebral 937 dexmedetomidine in video-assisted thoracic surgeries for acute and chronic 938 pain prevention. Pain Physician 2019; 22: 271-80. 939 940 71. Park R, Ho AM-H, Pickering G, Arendt-Nielsen L, Mohiuddin M, Gilron I. 941 Efficacy and safety of magnesium for the management of chronic pain in 942 adults: A systematic review: A systematic review. Anesth Analg 2020; 131: 764–75. 943 944 945